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Abstract 
Chronic respiratory diseases are a major cause of worldwide mortality and morbidity. 
Although hereditary severe deficiency of alpha 1 antitrypsin (A1AD) has been 
established to cause emphysema, A1AD accounts for only ~1% of Chronic 
Obstructive Pulmonary Disease (COPD) cases. Genome-wide association studies 
(GWAS) have been successful at detecting multiple loci harbouring variants 
predicting the variation in lung function measures and risk of COPD. However, 
GWAS are incapable of distinguishing causal from non-causal variants. Several 
approaches can be used for functional translation of genetic findings. These 
approaches have the scope to identify underlying alleles and pathways that are 
important in lung function and COPD. Computational methods aim at effective 
functional variant prediction by combining experimentally generated regulatory 
information with associated region of the human genome. Classically, GWAS 
association follow-up concentrated on manipulation of a single gene. However 
association data has identified genetic variants in >50 loci predicting disease risk or 
lung function. Therefore there is a clear precedent for experiments that interrogate 
multiple candidate genes in parallel which is now possible with genome editing 
technology. Gene expression profiling can been used for effective discovery of 
biological pathways underpinning gene function. This information may be used for 
informed decisions about cellular assays post genetic manipulation. Investigating 
respiratory phenotypes in human lung tissue and specific gene knockout mice is a 
valuable in vivo approach that can complement in vitro work. Herein, we review 
state-of-art in silico, in vivo and in vitro approaches that may be used to accelerate 
functional translation of genetic findings. 
 
 
 
 
 
  
3 
 
According to the World Health Organization, chronic respiratory diseases such as 
asthma or Chronic Obstructive Pulmonary Disease (COPD), are one of the leading 
causes of population morbidity and mortality (Mathers, 2008). Worldwide there are 
approximately 500 million people suffering from obstructive lung disease such as 
asthma and COPD. Asthma is a chronic inflammatory disorder associated with 
airway hyper responsiveness and reversible airway obstruction. COPD on the other 
hand is characterized by irreversible airway obstruction, and one or both of 
emphysema and chronic bronchitis. Although asthma and COPD are considered a 
public health problem in both developed and developing countries, most asthma and 
COPD related deaths occur in low income countries (Lozano et al., 2012). Both 
diseases are life-threatening and currently not curable. If patients are well managed 
and given the appropriate treatment, it can improve their quality of life and life 
expectancy. Nevertheless, the ultimate objective of the research carried out by the 
respiratory community is to be able to treat patients having chronic respiratory 
diseases by reversing the underlying pathophysiology. In order to do this 
successfully, it will be necessary to develop novel therapeutic agents and strategies 
targeting the underlying cascade of biological events leading to disease.  
Functional genomics has the potential to accelerate the discovery of pathways 
involved in the pathogenesis of chronic respiratory diseases. The development of 
high-throughput genotyping and next generation sequencing (NGS) accompanied by 
development of the necessary bioinformatic analytical tools has allowed for massive 
and successful undertakings to identify genetic variation predicting respiratory 
disease status or lung function (Mardis, 2011) and has started to pave the way to 
understand the functional basis of some of these signals. If applied effectively it 
should result in the generation of novel hypotheses that can be verified 
experimentally. In the current review we describe historical and current genetic 
studies that have investigated respiratory phenotypes as well as in silico, in vitro and 
in vivo approaches to facilitate the biological and therapeutic translation of these 
findings.     
Genetics of lung function and COPD 
The last 10 years has seen a dramatic increase in the number of studies examining 
the genetic basis of lung function measures and COPD due to the development of 
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relatively cheap platforms for genotyping subjects on a genome wide basis with 
adequate coverage to permit genetic association signals to be detected. This has led 
to a number of high quality GWAS publications on a range of respiratory related 
phenotypes. 
Definition of lung function and COPD phenotypes 
Although it is beyond the scope of this review to describe the phenotypic 
manifestation of COPD in detail, some definitions need to be addressed before 
considering genetics. There are multiple measurements which can be made to 
assess lung function however the most commonly used are forced vital capacity 
(FVC) and forced expiratory volume in the first second (FEV1). These are 
unequivocal measurements with a general consensus regarding their derivation 
using spirometry (M. R. Miller et al., 2005). FVC is the volume of air that can be 
expired forcibly after full inspiration and is reduced in conditions that either limit 
inspiration or cause air trapping. FEV1 is the volume of air expelled in the first 
second of a maximal forced expiration from a position of full inspiration. FEV1 is 
reduced when airway obstruction is present: this is usually defined as <80% of the 
predicted value based on age, gender and height. However, these are not 
independent variables and any condition that reduces vital capacity affects FEV1. As 
in a healthy individual 70% of FVC is expelled in the first second airway obstruction 
is defined as a FEV1/FVC ratio of less than 0.7. Therefore, reduced FEV1/FVC 
defines airway obstruction, while FEV1 grades its severity (Rabe et al., 2007). COPD 
has previously been defined and graded using the GOLD criteria which are 
summarized in Table 1 (Hurd & Pauwels, 2002) and has recently been updated in 
2013 to consider symptoms and frequency of exacerbations ((GOLD), 2015). On the 
other hand forced expiratory flow between 25% and 75% of vital capacity (FEV25-75%) 
and FEV25-75%/FVC indices have been controversial in terms of value and relative 
diagnostic sensitivity. Some studies argued that FEV25-75% is a sensitive index of 
airway obstruction (Lebecque, Kiakulanda, & Coates, 1993; Simon et al., 2010), 
while other studies suggest this index is of limited value in this regard (Ciprandi et 
al., 2012). 
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Table 1: Spirometry defined GOLD standards of airway limitation severity in COPD  
Classification of severity of airway limitation in COPD based on post-
bronchodilator FEV1 
In patients with FEV1/FVC < 0.7 
GOLD 1 Mild FEV1 ≥ 80% predicted 
GOLD 2 Moderate 50% ≤ FEV1 < 80% predicted 
GOLD 3 Severe 30% ≤ FEV1 < 50% predicted 
GOLD 4 Very severe FEV1 < 30% predicted 
 
COPD is a leading cause of death and chronic morbidity throughout the world. 3 in 
every 1000 people are diagnosed with COPD each year and the incidence increases 
rapidly with age (Afonso, Verhamme, Sturkenboom, & Brusselle, 2011). The clinical 
presentation of COPD is diverse (Hansen, Sun, & Wasserman, 2007; Pellegrino et 
al., 2005). It is a progressive disabling condition characterized by airway limitation 
that is not reversible. Typical symptoms include dyspnea, chronic cough or sputum 
production but spirometry is considered to be a gold standard method for the 
diagnosis of COPD (Rabe et al., 2007). This is largely due to the fact that the clinical 
presentation of these conditions varies greatly between individuals highlighting 
COPD as a heterogeneous condition. Therefore COPD is clinically defined as post-
bronchodilator FEV1/FVC less than 70% predicted and FEV1 less than 80% 
predicted. FEV1 (Percent Predicted) includes adjustments for age, gender, and 
height (Hankinson, Odencrantz, & Fedan, 1999). Although cigarette smoking is a 
major risk factor for the development of COPD, only 15 to 20% of smokers manifest 
clinically significant COPD (J. J. Zhou et al., 2013). Inflammatory processes of 
COPD are located in central airways and are connected to increased mucous 
production, reduced ciliary clearance and a disrupted airspace epithelial barrier. 
Emphysema (parenchymal destruction) is a sub-phenotype of COPD and is 
characterized by enlargement of distal airspaces due to destruction of the airway 
walls (Hemminki, Li, Sundquist, & Sundquist, 2008b). 
Familial aggregation of spirometry measures and COPD in families 
Familial aggregation studies provide diverse but not completely consistent evidence 
implicating genetic factors in lung function phenotypes. The original twin study by 
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Hubert et al. demonstrated that lung function measures show heritability estimates to 
be above 70%, which suggested that most of the variation observed in the studied 
population is caused by genetic factors (Hubert, Fabsitz, Feinleib, & Gwinn, 1982). 
Redline et al. reported that monozygotic twins reared together showed intra-pair 
correlations of pulmonary function ranging from 0.5 to 0.7, while dizygotic twins 
reared together had correlations approximately one-half the magnitude of those for 
the monozygotic twins suggesting the presence of a significant genetic component 
(Redline et al., 1987). Subsequent cross-sectional studies report heritability ranging 
as high as 85% for FEV1, 91% for FVC, and 45% for FEV1/FVC ratio (Coultas, Hanis, 
Howard, Skipper, & Samet, 1991; Lewitter, Tager, McGue, Tishler, & Speizer, 1984; 
McClearn, Svartengren, Pedersen, Heller, & Plomin, 1994; Ober, Abney, & McPeek, 
2001; Wilk et al., 2000). Moreover, heritability of lung function measures was also 
found to be consistent through time (Lewitter et al., 1984). A more recent study by 
Hukkinen et al. revealed heritability estimates of 32% and 36% for FEV1, 41% and 
37% for FVC, while 46% and 16% for FEV1/FVC ratio at baseline and at later follow-
up, respectively (Hukkinen et al., 2011). The same group also found that differences 
in environmental effects explained ~60 to ~70% of observed variation suggesting 
spirometry measures to be complex phenotypes, where the individual variation is 
strongly affected by environmental effects.  
Silverman et al. have shown that the risk of COPD is ~2-3 higher in smokers who 
have a first degree relative affected by COPD suggesting the presence of hereditary 
factors contributing to COPD pathogenesis (Silverman et al., 1998). In agreement 
with these estimations McCloskey et al. found that the odds ratio of having COPD if 
a sibling has the disease is approximately five (McCloskey et al., 2001). Hemminki et 
al. reported that singleton siblings and twins have much higher risks of emphysema 
and chronic bronchitis than their parents (Hemminki, Li, Sundquist, & Sundquist, 
2008a). Considering the fact that both siblings and partners usually share roughly 
the same environment, the study was able to provide genetic epidemiological 
evidence for a heritable aetiology in COPD. The heritability of chronic bronchitis 
which is one of the main conditions underlying COPD, was evaluated at 40% 
(Hallberg et al., 2008). Recently, Zhou et al. reported the first estimate of 
emphysema heritability at 25% (J. J. Zhou et al., 2013). Taken together these 
studies demonstrate a significant familial aggregation of lung function, and other 
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COPD related phenotypes which have motivated research efforts to identify genetic 
variants predisposing to airway obstruction. 
Standing on the shoulders of giants: a brief historical overview of molecular 
genetics and functional studies in pulmonary physiology 
The discovery of α-1-antitrypsin (A1AT) deficiency as a cause of emphysema 
The first gene linked to emphysema was SERPINA1 encoding serine protease α1-
antitrypsin (A1AT). A1AT is a member of the serine protease inhibitor superfamily 
(SERPINS) and phylogenetic analyses indicate its evolutionary conservation in 
higher animals, nematodes, insects, plants, and viruses (Irving, Pike, Lesk, & 
Whisstock, 2000). The path that led to the discovery of A1AT deficiency as a risk 
factor for emphysema has a long history. It began with studies by Fermi and 
Pernossi in 1894 and later by Pugliese and Coggi in 1897 that noted protease 
inhibitor activity of the human plasma due to its preventative action upon trypsin. It 
took half a century to isolate the main inhibitor responsible for antiprotease activity 
which was named A1AT because of its location in the α1-globulin fraction and its 
ability to inhibit trypsin (for a review describing these initial discoveries see 
(Janciauskiene et al., 2011)). In 1963, Laurell and Eriksson reported that patients 
with pulmonary lesions suffering from severe respiratory deficiency had markedly 
reduced levels of A1AT (Laurell & Eriksson, 2013). They noted that some patients 
were relatives and attributed their clinical pathology to potential ‘inborn error’. At a 
later date, Eriksson gathered a substantial collection of A1AT cases including their 
families providing comprehensive evidence of the link between A1AT deficiency and 
emphysema (Eriksson, 1965). Subsequently, Lieberman showed that serum 
deficiency of A1AT is greater in homozygotes and heterozygotes with the 
susceptibility allele than in individuals with the normal “healthy” allele (Lieberman, 
1969). He concluded that Z allele predisposes to pulmonary emphysema. The 
plasma levels of A1AT in individuals that have at least one copy of the Z allele is 
approximately 10 to 15% of the normal levels (Eriksson, 1965). Taking all these 
studies together it became accepted that A1AT homoeostasis is necessary for 
pulmonary health and that A1AT imbalance may lead to pathological decline in lung 
function due to excessive protease activity in the airways. Many genetic variants of 
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A1AT were identified some of which altered the plasma levels of A1AT while others 
were structural in nature (for a review see (DeMeo & Silverman, 2004)).  
Later studies revealed that although most patients with A1AT deficiency suffer from 
emphysema, this deficiency occurs in only 1 to 3 % of the COPD population (Stoller 
& Aboussouan, 2005). Therefore despite the unprecedented genetic, molecular and 
mechanistic advances in the understanding of A1AT deficiency as causative in 
emphysema, it is still not clear what the underlying biological processes giving rise to 
COPD are in the majority of patients. Current therapeutic strategies to treat A1AT 
deficiency include preventative measures (smoking cessation) and, in some 
countries, A1AT replacement therapy.  
Genetic mapping of lung function genes: linkage analyses 
Genetic mapping is the process of localization of genomic loci harbouring genetic 
variation which can contribute to the phenotypic variation of either a continuous trait 
or dichotomous state. Perhaps the biggest advantage of genetic mapping is the fact 
that it can be performed in a hypothesis free fashion without any prior knowledge 
about the gene’s biological functions. Therefore it allows the unbiased discovery of 
candidate disease susceptibility genes. The underlying principle of genetic mapping 
is the identification of association between a recognized genetic marker (i.e. 
polymorphic variant whose genomic location is known) and the phenotype. If a 
particular marker is showing correlated segregation with a trait it is said that this 
marker is in linkage with the ‘causative variant’ associated with the trait under study. 
Typically linkage studies for human traits involve genotyping families that contain 
multiple affected individuals for 300-400 microsatellite markers, such as short 
tandem repeats (STR), that span the whole genome and testing for co-segregation 
of a trait and marker alleles (Lander & Schork, 1994).  
The proximity of a marker to a gene can be estimated by measuring the number of 
recombination events between them, measured as a recombination fraction (). The 
closer two loci are, the lower the probability that they will be separated during 
meiosis. The relationship between recombination fraction () and map distance is 
that equal to 0.1 corresponds to 10cM and, although variable, 1cM roughly 
corresponds to one megabase of DNA in the human genome. The statistical 
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significance of the linkage is commonly measured by the LOD score, which is the log 
of the ratio of the data's likelihood given linkage to the likelihood of no linkage or a P 
value. A LOD score of 3.3 corresponds to a P value of 5 x 10-5, which is the 
recommended threshold for genome wide scans (5% false positives at this 
stringency). A LOD score of 2.2 (P = 7 x 10-4) is suggestive of linkage, 3.6 (P = 2 x 
10-5) corresponds to significant linkage and a score of 5.4 (P = 3 x 10-7) is highly 
significant linkage.  
There have been several studies that performed genome-wide linkage scans to 
reveal susceptibility loci for airway obstruction and these studies focused on both 
lung function measures as well as COPD diagnosis. The first study to do linkage 
analysis for COPD related phenotypes was by Silverman et al. (Silverman, Mosley, 
et al., 2002). These analyses were performed on pedigrees ascertained through 
severe and early-onset COPD without A1AT deficiency. Following the criterion of 
significant linkage as LOD score above 3.3 no loci showed significant linkage. 
However another study by Silverman et al. in the same year, focused exclusively on 
spirometry measures and significant evidence for association to FEV1/FVC was 
demonstrated on chromosome 2q with LOD score of 4.12 at 222 cM (Silverman, 
Palmer, et al., 2002). Restricting the analysis to smokers increased the statistical 
significance of linkage suggesting gene-by-smoking interaction as contributing to 
disease development. None of the other markers tested for association with 
FEV1/FVC had a LOD score above 3.3. FEV1 did not show any evidence of linkage 
(based on LOD score). Again, restricting the analysis to smokers increased the LOD 
scores suggesting gene-by-smoking interaction as contributing to disease 
development. Other linkage studies for lung function and COPD phenotypes are 
summarized in Table 2 below.  
Overall, linkage studies have had a limited success in investigating association of 
genetic variants to lung function and COPD. This is probably due to a fact that 
linkage analyses, although highly effective in studying monogenic disorders (such as 
cystic fibrosis), are not optimal and do not have the power to identify genetic variants 
for complex, multifactorial diseases and traits. Importantly, the late onset of COPD 
makes it difficult to perform family based studies in large numbers of subjects limiting 
this kind of study design and approach to gene identification.   
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Table 2: Summary of main genetic linkage studies for lung function and COPD phenotypes (Celedon et 
al., 2004; DeMeo & Silverman, 2003; Palmer et al., 2003; Wilk et al., 2003). 
Locus Measure LOD score Reference 
Chr.12 at 35cM  FEV25%-75% 5.03 DeMeo et al. (2004) 
Chr.6 at 184cM FEV1 5 Wilk et al. (2003) 
Chr.2q FEV1/FVC 4.42 Palmer et al. (2003) 
Chr.2 at 229cM FEV1/FVC 4.13 DeMeo et al. (2004) 
Chr.2 at 221cM FEV25%-75%/FVC 4.12 DeMeo et al. (2004) 
Chr.4 at 28cM FEV1/FVC 3.5 Wilk et al. (2003) 
Chr.12 at 35cM FEV25%-75%/FVC 3.46 DeMeo et al. (2004) 
Chr.19q  FEV1 3.3 Celedon et al. (2004) 
Chr.8p  FEV1  3.3 Palmer et al. (2003) 
Chr.12 at 36cM FEV1/FVC 3.26 DeMeo et al. (2004) 
 
 
Candidate gene studies  
DeMeo et al. performed a follow-up study to identify the most likely causative gene 
behind the linkage signal on chromosome 2 (Demeo et al., 2006). This was achieved 
by interrogating the transcriptomic profiling with genetic approaches. Although it was 
not explicitly mentioned in the publication, DeMeo et al. hypothesised that genes that 
appear to be differentially expressed at different stages of embryonic lung 
development would have a role in lung embryogenesis, which would in turn explain 
the observed linkage peak for chromosome 2. The limitation of this approach is that 
a gene that is differentially expressed during lung development does not show this 
gene to play a per se role in lung development. DeMeo et al. used a mouse 
microarray dataset to measure the differential expression of genes located within the 
linkage interval. The serpin peptidase inhibitor, clade E, member 2 (SERPINE2) 
gene was found to have the greatest change in expression across the developmental 
time series. Therefore SERPINE2 was taken forward for further investigation. 
Researchers also had other reasons to pursue this path, including the fact that 
SERPINE2 encodes a cellular and extracellular matrix-associated serine protease 
inhibitor known to be involved in coagulation, fibrinolysis and protease homeostasis 
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which is also true for A1AT. Leveraging a lung microarray dataset from a population 
of COPD subjects and healthy controls, SERPINE2 expression was found to be 
significantly correlated with various respiratory parameters such as lung 
hyperinflation and post bronchodilator FEV1 (Demeo et al., 2006). SERPINE2 
expression was only moderately increased in COPD (1.25 fold difference) and the 
observed effect did not meet the 5% false discovery rate. Immunohistochemistry 
(IHC) was used to demonstrate SERPINE2 expression in both mouse and human 
lung tissue. In human lung positive staining was demonstrated in healthy, 
emphysematous, and asthmatic lungs. Crucially, although Zhu et al. provided an 
independent and strong replication of genetic association of SERPINE2 as a 
susceptibility gene for COPD, Chappell et al. did not replicate an association of 5 
single nucleotide polymorphisms (SNPs) of the SERPINE2 gene with COPD 
(Chappell et al., 2006; Zhu et al., 2007). SERPINE2 is ~64kb in size and some of the 
5 genotyped SNPs are not in strong linkage disequilibrium (LD). This suggests the 
presence of homologous recombination hotspots within the SERPINE2 gene 
(Chappell et al., 2006). Therefore relying on 5 variants to replicate a genetic 
association is limiting since it may miss those SNPs that are driving the observed 
association but are not in linkage with genotyped SNPs. Zhu et al. used 25 SNPs in 
their replication of SERPINE2 association with COPD and this highlighted the need 
to use a sufficient number of genotyped variants in order to properly examine a given 
gene (Zhu et al., 2007). What can be learned from these studies is the fact that 
although common haplotypes may appear to be associated with a given trait, in 
different populations the same SNPs may not be associated with the same 
phenotypes. This complex pattern of association is not surprising in multifaceted 
diseases or traits such as COPD and lung function measures, and points towards 
the importance of conducting functional studies aiming at assessing the effect of 
SNP variation on gene function or expression. It is particularly intriguing that, as is 
the case for SERPINE2, a region of the gene shows association with a given 
phenotype but another region of the same gene may not be associated at all. This 
further emphasizes the need to perform functional studies upon candidate SNPs to 
confirm relevant causative genes. More recently, in a GWAS of airway wall thickness 
(AWT) it was identified that SNPs within SERPINE2 were associated with AWT and 
reduced levels of SERPINE2 in human lung tissue (Dijkstra, Postma, et al., 2015).   
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The starting point for another study by DeMeo et al. was a publicly available 
microarray dataset of differentially expressed probe sets in human lung tissue 
stratified by lung function measures. Genomic regions appearing as differentially 
expressed were LD tagged and 889 SNPs from identified haplotypes were selected 
for association testing with COPD. Among these, 71 SNPs were significant at a 
nominal level (i.e. without correction for multiple comparisons) and taken forward for 
replication in a separate population. A stringent threshold of significance was 
established and only SNPs present on the iron regulatory protein 2 (IREB2) gene 
met statistical significance. Finally, IREB2 mRNA and protein expression were 
shown to be significantly increased in lung tissue samples from COPD subjects in 
comparison to healthy controls implicating IREB2 as a COPD susceptibility gene. 
Therefore, DeMeo et al. firstly combined transcriptomics as well as genomics to 
inform the candidate COPD SNPs selection, and secondly followed this by a genetic 
association study, finally showing up-regulation of the putative gene in a disease 
state. Although IREB2 may act as a marker for COPD, at this stage it is not clear 
whether its levels are causal in relation to COPD pathogenesis or whether it is simply 
an epiphenomenon of other COPD causal mechanisms.  
In addition to candidate genes from linkage regions there have been a large number 
of candidate gene studies in COPD. Many of these suffered from limited coverage of 
the genetic variation in target genes and small sample sizes thus limiting 
interpretation due to the lack of replication. These studies have been reviewed in 
detail elsewhere (Hardin M, 2014). Of note, a well powered study (8,300+ subjects) 
using a candidate gene approach identified association between SNPs in the matrix 
metalloprotease 12 gene (MMP12) and both FEV1 and COPD risk (Hunninghake et 
al., 2009). 
Genome-wide association (GWA) studies  
The advent of genome-wide association (GWA) studies is attributable to advances in 
genotyping technology (Syvanen, 2005), the Human Genome Project (Venter et al., 
2001) and the completion of the HapMap project (International HapMap, 2005). In 
GWAS, hundreds of thousands of SNPs in large populations are assayed to 
determine the co-occurrence of these variants with disease symptoms or with certain 
trait distribution (Pearson & Manolio, 2008). Importantly these SNPs are selected to 
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capture the maximum information on the human genome by using optimised panels 
that tag haplotype blocks which is made possible by our improved understanding of 
the human genome, thanks to the initiatives such as HapMap (International HapMap, 
2005). Since GWAS is a population-based approach, most GWAS have 
concentrated on looking for association with common variants (>5%) and they are 
generally less well designed to evaluate low allele frequency variants (Hirschhorn & 
Daly, 2005). This is in contrast to family-based linkage approaches which are ideally 
suited for detecting rare genetic variants of large phenotypic effect. However GWAS 
generally offer greater resolution and more power in association mapping. GWAS 
rely on appropriate reconstruction of haplotypes based on population data however 
results may be misleading if this reconstruction is erroneous. This is because 
investigators may use one SNP (also known as tag SNP) as a proxy for a number of 
other SNPs present on the same haplotype. Importantly, the boundaries of haplotype 
blocks vary between populations of different ancestries which complicates cross-
sectional comparison of studies that leveraged different ethnic populations 
(International HapMap, 2005). As in linkage scans, GWAS can be conducted in a 
hypothesis free fashion without any prior knowledge about trait or gene function. 
Nevertheless, as in any association mapping, they can only identify SNPs in LD with 
causal SNPs but cannot pinpoint the causal SNP or gene (Hirschhorn & Daly, 2005). 
GWAS typically examine association with 500,000+ common polymorphisms 
spanning the entire genome in cases and controls which therefore requires very 
stringent statistical thresholds (e.g. P < 5 x 10-8) to limit the risk of type I error.  
The landscape of GWAS for lung function and COPD 
Meta-analyses of FEV1 
Individual GWAS of lung function measures have identified a number of candidate 
SNPs potentially involved with human lung function measures FEV1 and FEV1/FVC. 
Notably, between 2006 - 2010 there were four small GWAS utilizing high throughput 
SNP genotyping with traits; lung function (Wilk et al., 2009; Wilk, Walter, Laramie, 
Gottlieb, & O'Connor, 2007) and COPD (Cho et al., 2010; Pillai et al., 2009). These 
studies identified several genetic loci underlying these traits including e.g. Hedgehog 
Interacting Protein (HHIP), nicotinic acetylcholine receptor 3/5 (CHRNA3/5) and 
Family with sequence similarity 13, member A (FAM13A) (Cho et al., 2010; Pillai et 
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al., 2009; Wilk et al., 2009; Wilk et al., 2007). The CHRNA3/5 signal is likely to be 
driven by tobacco addiction. Importantly, while these studies demonstrated the 
potential to identify novel lung function and COPD loci using GWA approaches it was 
clear that greater statistical power was required to identify genes with confidence 
indicating the need for very large population sizes. 
This led to the use of meta-analyses, i.e. analysing the results of many separate 
GWAS together to increase study power for novel gene discovery. A key component 
of these meta-analyses is the use of imputation whereby genetic variation not 
directly genotyped on the specific genotyping platform can be inferred with a 
measurable degree of confidence using reference genomes now available from the 
HapMap project and subsequently the 1000 and 10,000 genomes initiatives 
(Marchini & Howie, 2010). This approach makes possible the combining of 
genotyping data generated on a diverse number of genotyping platforms from 
individual studies. 
The first two of these studies was the SpiroMeta and Charge consortium studies that 
investigate FEV1 and FEV1/FVC and were published as back to back papers in 2010 
(Hancock et al., 2010; Repapi et al., 2010). These studies had large discovery and 
replication samples.  In Spirometa the sample sizes were 20,288 in the discovery 
population and 21,209 in the replication population: imputation resulted in testing for 
2.5 million genotyped and imputed SNPs  (Repapi et al., 2010).  
Forced Expiratory Volume in 1 second 
In the SpiroMeta study four loci were reported as reaching genome wide significance 
for FEV1 including common variants at novel loci; 2q35 in Tensin 1 (TNS1), 4q24 in 
Glutathione S-Transferase, C-Terminal Domain Containing (GSTCD), and 5q33 in 5-
Hydroxytryptamine (Serotonin) Receptor 4 (HTR4) and in the previously reported loci 
at 4q31 in HHIP (see Figures 1 and 2).  
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Figure 1: Manhattan plot of association results for FEV1 from the SpiroMeta Study. Plot ordered by 
chromosome position. SNPs with −log10 P > 5 are indicated in red. The four loci indicated by arrows 
showed association with FEV1 (P < 5 × 10−8) in the meta-analysis. Figure reproduced from (Repapi et al., 
2010). Reprinted by permission from Macmillan Publishers Ltd: [Nature Genetics] (January; 42(1):36–44, 
doi:10.1038/ng.501), copyright (2010). 
 
Focussing in on specific loci associated with FEV1 shows the sentinel SNPs involved 
at loci 2q35, 4q24 and 5q33, potentially involving TNS1, GSTCD and HTR4, 
respectively (Figure 2). These data illustrate typical genetic association signal 
observed in GWAS as the signal can be relatively broad spanning many potential 
candidate genes and involving extended linkage disequilibrium making identification 
of the causative variant and gene a challenge.  
Importantly, the Charge consortium again using a large discovery population of 
20,890 subjects also showed genome wide association with FEV1 at the 
INTS12/GSTCD/NPNT locus as well as describing additional signals (Hancock et al., 
2010). This region encompasses genes Intergrator Complex Subunit 12 (INTS12), 
GSTCD and nephronectin (NPNT). In Repapi et al the most significant association 
was with rs10516526 within an intron of GSTCD (P = 2.18 x 10-23), whereas 
Hancock and colleagues study found the most significant association to involve SNP 
rs17331332 located near NPNT (P = 4.00 x 10-10) (Table 1) (Hancock et al., 2010; 
Repapi et al., 2010). 
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Figure 2: Regional association plots of three FEV1-associated loci in the SpiroMeta study. 2q35 (a), 4q24 
(b) and 5q33 (c). Statistical significance of each SNP on the −log10 scale as a function of chromosome 
position (NCBI build 36) in the meta-analysis. The sentinel SNP at each locus is shown in blue; the 
correlations (r2) of each of the surrounding SNPs to the sentinel SNP are shown in the indicated colours. 
Adapted from (Repapi et al., 2010) by permission from Macmillan Publishers Ltd: [Nature Genetics] 
(January; 42(1):36–44, doi:10.1038/ng.501), copyright (2010).  
 
To date, seven meta-analyses of GWAS have now been completed and identified 
SNP associations with FEV1 and/or FEV1 decline (Hancock et al., 2012; Hancock et 
al., 2010; Repapi et al., 2010; Soler ArtigasLoth, et al., 2011; Soler Artigas M, 2015; 
Tang et al., 2014; Wain L, 2015).  
Sixteen genetic loci have been identified associated with FEV1 and 18 loci have 
been associated with either FEV1 decline, rate of FEV1 change or an extreme of 
FEV1 using meta-analyses approaches. The most reproducible locus associated with 
FEV1 from lung function GWAS meta-analyses across all studies is the 4q24 locus 
(Table 3).  
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Table 3: Summary of meta-analyses of genome-wide associations with cross sectional and longitudinal 
FEV1. All samples were of European ancestry. 
Legend: #: participants had ≥ 3 measurements taken for FEV1 and the rate of change 
(mL/year) calculated. 
Meta-analyses of FEV1/FVC 
In an analogous manner to the FEV1 analyses, SNPs associated with FEV1/FVC 
have also been identified using GWAS meta-analyses. Again in the SpiroMeta and 
Charge consortia papers, several loci met conventional genome wide significance 
including variants in HHIP (Hedgehog interacting protein, 4q31), AGER (Advanced 
glycosylation end product-specific receptor, 6p21) and THSD4 (Thrombospondin, 
Type I, Domain Containing 4, 15q25) HTR4, ADAM Metallopeptidase Domain 19 
(ADAM19), Adhesion G Protein-Coupled Receptor G6 (GPR126) and THSD4. 
(Figures 3 and 4, Table 4) Hedgehog-interacting protein is a known morphogen 
shown to be involved in many developmental processes, inhibiting hedgehog 
signalling. SNP rs2070600 in exon 3 of the Advanced Glycosylation End Product 
18 
 
Receptor gene was found associated with FEV1/FVC in 2 meta-analyses (Hancock 
et al., 2010; Repapi et al., 2010). AGER encodes RAGE, a multiligand receptor 
implicated in homeostasis, development, inflammation and diseases including 
diabetes, Alzheimer’s and COPD (Bierhaus & Nawroth, 2009; Cheng et al., 2013; 
Ferhani et al., 2010; Hofmann et al., 2002; Hori et al., 1995; Sparvero et al., 2009; 
Wu, Ma, Nicholson, & Black, 2011; Yan et al., 1996). Associations were also 
identified for GPR126 encoding an adhesion G protein coupled receptor, whilst 
Thrombospondin, Type I, Domain Containing 4 (THSD4) encodes a potential 
metalloproteinendopeptidase. Recently, a new meta-analyses by Soler-Artigas and 
colleagues has revealed 6 further novel loci and 2 novel signals associated with 
FEV1/FVC (Soler Artigas M, 2015; Wain L, 2015). Novel signals in both NPNT and 
GPR126 were identified.  
Figure 3: Manhattan plot of association results for FEV1/FVC from the SpiroMeta Study. Plot ordered by 
chromosome position. SNPs with −log10 P > 5 are indicated in red. The four loci indicated by arrows 
showed association with FEV1 (P < 5 × 10−8) in the meta-analysis. Figure reproduced from (Repapi et al., 
2010). Reproduced by permission from Macmillan Publishers Ltd: [Nature Genetics] (January; 42(1):36–
44, doi:10.1038/ng.501), copyright (2010). 
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Figure 4: Regional association plots of three FEV1/FVC-associated loci, 4q31 (a), 6p21 (b) and 15q23 (c). 
Statistical significance of each SNP on the −log10 scale as a function of chromosome position (NCBI 
build 36) in the meta-analysis. The sentinel SNP at each locus is shown in blue; the correlations (r2) of 
each of the surrounding SNPs to the sentinel SNP are shown in the indicated colours. Adapted by 
permission from Macmillan Publishers Ltd: [Nature Genetics] (January; 42(1):36–44, doi:10.1038/ng.501), 
copyright (2010).  
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Table 4: Summary of meta-analyses of genome-wide associations with FEV1/FVC. All samples were of 
European ancestry. 
 
Interestingly, SNPs in HHIP and HTR4 were found to be significantly associated with 
both FEV1 and FEV1/FVC. SNP rs12604628 was associated with both lung function 
measures (Repapi et al., 2010) whilst for HTR4, different SNPs were identified in 
each case (Hancock et al., 2010; Repapi et al., 2010). 
Genome-wide association studies and meta-analyses in COPD 
In addition to associations with FEV1 and FEV1/FVC, unsurprisingly these SNPs 
have also been associated with COPD susceptibility (Table 5) (Brehm et al., 2011; 
Castaldi et al., 2011; W. Chen et al., 2015; Cho et al., 2010; Cho et al., 2012; Kim et 
al., 2014; Pillai et al., 2009; Soler Artigas, Wain, et al., 2011; Soler Artigas M, 2015; 
Van Durme et al., 2010; Wilk et al., 2012). Moreover, recent studies have identified 
more refined and disease specific SNP associations in COPD subtypes including; 
emphysema (Kong et al., 2011; Pillai et al., 2010), COPD exacerbations (Pillai et al., 
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2010), mild-moderate COPD (Hansel et al., 2013), moderate-severe COPD (Cho et 
al., 2014) and Chronic Bronchitis (J. H. Lee et al., 2014) (Table 5). 
Table 5: Genome-wide association studies and GWAS meta-analyses of COPD 
 
 
Legend: * Trend did not reach significance 
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Chromosomes 2q, 4q, 5q, 15q and 17q had regions with numerous SNPs associated 
with COPD diagnosis. SNPs with the lowest P values studied (P ≤ 1 x 10-9) were in 
or near to FAM13A (Cho et al., 2010; Cho et al., 2012; Cho et al., 2014; J. H. Lee et 
al., 2014), HHIP (Cho et al., 2014; Van Durme et al., 2010), Cholinergic Receptor, 
Nicotinic, Alpha 3 (Neuronal) (CHRNA3) (Cho et al., 2014; Pillai et al., 2009), ACN9 
(renamed SDHAF3, Succinate Dehydrogenase Complex Assembly Factor 3) (Kim et 
al., 2014), RAS oncogene family member, RAB4B (Cho et al., 2012) and AGPHD1 
(renamed HYKK) a hydroxylysine kinase (Wilk et al., 2012).  
Genes with significant SNPs in both Table 3 (FEV1) and Table 5 (COPD) included 
TNS1 SNP rs2571445 (Repapi et al., 2010; Soler Artigas, Wain, et al., 2011), many 
SNPs at the 4q24 locus (Castaldi et al., 2011; Repapi et al., 2010; Soler Artigas, 
Wain, et al., 2011), SNP rs12604628 in HHIP (Repapi et al., 2010; Soler Artigas, 
Wain, et al., 2011), rs3995090 in HTR4 (Repapi et al., 2010; Soler Artigas, Wain, et 
al., 2011) and SNPs in SRY (Sex Determining Region Y)-Box 9 (SOX9) (Hancock et 
al., 2012; Kim et al., 2014). For SNPs associated with FEV1/FVC and COPD, 
different SNPs in Transforming Growth Factor, Beta 2 (TGFB2) were identified (Cho 
et al., 2014; Soler Artigas, Wain, et al., 2011), rs2869967 in FAM13A (Hancock et 
al., 2010; J. H. Lee et al., 2014), rs12504628 in HHIP (Repapi et al., 2010; Soler 
Artigas, Wain, et al., 2011) and different SNPs in HTR4 (Hancock et al., 2010; Soler 
Artigas, Wain, et al., 2011; Wilk et al., 2012). Overall these data show genetic 
variants that were originally identified as genetic determinants of lung function in a 
general population are also associated with COPD. 
Refining COPD SNP associations 
The identification of SNPs associated with COPD susceptibility, GOLD stages and 
COPD sub-types have been aided by utilising data collected in several worldwide 
initiatives including; COPDGene, ECLIPSE (Evaluation Of COPD Longitudinally to 
Identify Predictive Surrogate Endpoints), NETT (National Emphysema Treatment 
Trial), and GenKOLS (Genetics of COPD, Norway) studies, which provide large 
datasets of clinical, computed tomography (CT) and spirometric information on 
COPD subjects. These studies are continuing to investigate the underlying genetic 
and heritable factors of COPD e.g. using data collected from over 10,000 individuals 
in the case of COPDgene. With the use of CT scans, COPDGene® seeks to better 
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classify COPD based on the pathology observed and understand how the disease 
may differ from person to person. Furthering our understanding of the genetics 
underlying clinical features of COPD, Cho et al. recently published findings using 
these cohorts. By completing a GWAS of CT imaging phenotypes, 5 genetic loci 
were found to be associated with emphysema-related phenotypes, one locus 
associated with airway related phenotypes and 2 loci with gas trapping (Table 6) 
(Cho et al., 2015). The finding that genetic variants associated with both lung 
function and COPD risk also associate with emphysema related phenotypes e.g. 
AGER SNP rs2070600 is of critical importance as this i) provides greater confidence 
that this locus is a true association and ii) begins to help dissect the altered biological 
mechanisms that may underlie the association i.e. parenchymal destruction.    
Table 6: Phenotypic genetic associations in COPD 
 
%LAA2950 = percentage low attenuation area, using a threshold of 2950 HU; 
Perc15 = HU at the 15th percentile of the density histogram; WAP = percentage of 
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the wall area compared to the total bronchial area. CMH = Chronic Mucus 
Hypersecretion. LHE = local histogram-based emphysema. 
Also trying to further stratify the complex genetics of COPD, a recent study by 
Dijkstra and colleagues questioned whether the same SNPs were related to the 
chronic mucus hypersecretion (CMH) in smokers with and without COPD (Dijkstra, 
Boezen, et al., 2015). In a meta-analysis of GWAS, the top SNP associated with 
CMH in smokers with COPD was located in GDNF, whilst 4 other CMH associated 
SNPs in smokers without COPD were also identified (Table 6). Also in 2014, 
Manichaikul et al. identified associations in percentage emphysema using computed 
tomography scans (Table 6). Furthermore, on comparison of upper and lower lobes 
in the CT scans of Hispanic individuals, a difference in emphysema lobe ratio was 
found to be associated with a SNP in MAN2B1 (Manichaikul et al., 2014). A separate 
study by Castaldi et al. used the quantification results of computed tomography 
emphysema to identify SNPs associated with 4 distinct patterns of emphysema 
(normal, moderate centrilobular, severe centrilobular and panlobular) (Castaldi et al., 
2014).    
The missing hereditability 
To date, ~49 distinct lung function loci have been identified.  However it is estimated 
that they explain only a modest proportion of the additive polygenic variance (4% for 
FEV1, 5.5% for FEV1/FVC and 3.2% for FVC). There are several reasons for this gap 
or “missing hereditability”. GWAS focus on common polymorphisms with minor allele 
frequency greater than 5% that span a small fraction of the human genome, but 
other forms of genetic variation may be important particularly rare variation and 
structural variation including copy number variants (S. Lee, Abecasis, Boehnke, & 
Lin, 2014). Therefore common SNPs either individually or taken together typically 
may only explain only a small fraction of phenotypic variance. Leveraging larger 
population sizes may improve the determination of true underlying genetic variance 
that accounts for phenotypic variance in lung function measures and COPD. 
Recently in 2013, Klimentidis et al. applied a method developed in the animal 
breeding field to estimate the heritability of the three main lung function measures 
FEV1, FVC, and FEV1/FVC (Klimentidis et al., 2013). From their all-SNP-inclusive 
analysis that considered all the genotyped SNPs they found that heritability using 
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SNP data are nearly identical to estimates based on pedigree information (range 
from 0.50 for FEV1 to 0.66 for FEV1/FVC). However, relying on entire whole-genome 
SNP data is unlikely to yield accurate approximation of heritability because only 
single nucleotide or copy-number variants in LD with causative variants should be 
included in the heritability calculation. Ultimately whole genome sequencing 
associations with lung function measures are likely to help refine the estimate of 
genetic variation contributing to the phenotypic variation.  
Copy number variation in lung function and COPD 
In addition to SNPs potentially contributing to human lung function and COPD 
susceptibility, copy number variation (duplication or deletion of regions of DNA, 
CNVs) is also an important area of study, with 4% of the genome harbouring copy 
number variants (Conrad et al., 2010). For example, previous reports have identified 
the Beta Defensins to have 2-10 copies in the UK population (Fode et al., 2011; 
Hardwick et al., 2011). CNVs are associated with a number of diseases including 
immune-related diseases; psoriasis and Crohn’s disease (Bentley et al., 2010; 
Fellermann et al., 2006; Hollox et al., 2008). In 2011, Lee et al performed a GWAS of 
copy number variation to test for associations with lung function measures in the 
Korea Associated Resource (KARE) cohort (B. Y. Lee, Cho, Shin, & Kim, 2011). 
Interestingly, TNS1 and HTR4 showed evidence when leveraging copy number 
variation, which have previously been identified in SNP association studies (Hancock 
et al., 2010; Repapi et al., 2010). Recent work in a European study cohort however, 
did not support previously described associations for lung function measures and 
COPD susceptibility at the Beta Defensin1 locus (Wain et al., 2014).   
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In silico approaches in translational studies 
In previous sections we have summarized GWAS that have been successful in 
identifying SNPs associated with lung function and COPD diagnosis and phenotypes 
with a particular focus on meta-analyses. Despite these successes there is an 
obvious gap between these genetic findings and their functional and mechanistic 
translation (Visscher, Brown, McCarthy, & Yang, 2012). 
Over 90% of SNPs identified in GWAS of a range of human conditions and traits 
have been found to localize outside protein-coding regions and this has limited the 
rate of functional translation (Maurano et al., 2012). This is also true for lung function 
and COPD associations. This suggests that lung function and COPD associated 
variants are likely to be involved in normal and aberrant regulation of gene 
expression. Providing support for this, GWAS SNPs were found to be enriched in 
chromatin regulatory features (Maurano et al., 2012) and over-represented in gene 
expression quantitative trait locus (eQTL) studies (Nicolae et al., 2010). Since gene 
expression signatures are cell type specific and dependent on developmental stage 
and epigenetic mechanisms, as well as environmental factors, it makes interpretation 
of putative SNPs identified in GWAS challenging. SNPs located within intergenic 
regions are particularly difficult to interpret. In silico approaches to functionally 
translate genetic findings can facilitate interpretation and generate testable 
hypotheses.  
The Encyclopaedia of DNA Elements (ENCODE) project 
In silico translational approaches have become possible due to the widespread 
availability of regulatory information on the human genome generated from a diverse 
set of tissue and cell types. The Encyclopaedia of DNA Elements (ENCODE) project 
have taken a critical and leading role in this field. This initiative was launched in 2003 
by the United States National Human Genome Research Institute (NHGRI) as a 
follow up to Human Genome Project (Consortium, 2004). This project involves a 
worldwide consortium and the data generated can be accessed through public 
databases. The main motivation for ENCODE project was that the mere sequence of 
a reference haploid genome only provides the physical context of hereditary 
information and is difficult to interpret without an additional layer of regulation that 
determines how the cell reads the genetic code. Also, because only 1.5% of the 
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genome codes for protein, the project aimed at increasing our understanding of the 
remaining component of the genome which traditionally was inadequately 
understood (Ohno, 1972). Surprisingly, one of the ENCODE project 
accomplishments was to demonstrate that 80% of the genome is “associated with at 
least one biochemical function” (Maher, 2012). The ENCODE project passed through 
a pilot phase (Consortium et al., 2007), and currently is in the data production phase. 
Readers are advised to refer to Qu and Fang for a brief review with some more 
details of the ENCODE project (Qu & Fang, 2013).   
Integrating human genome regulatory information with candidate loci 
The fundamental assumption behind all translational in silico approaches is that trait 
associated SNPs should lie within a functionally annotated region. These functional 
annotations involve biological or chemical events typically identified via high 
throughput techniques (Schaub, Boyle, Kundaje, Batzoglou, & Snyder, 2012). For 
example in the hypothetical locus displayed in Figure 5, six SNPs are in strong LD as 
demonstrated by an r2 close to 1. Out of these polymorphisms, SNP 1 was the 
genotyped sentinel SNP and hence had the most significant P-value in the 
association study. However, SNP 1 does not associate with any of the available 
regulatory annotations making this SNP unlikely to be driving the observed 
association signal. On the other hand, SNP 6 associates with a DNaseI 
hypersensitive site (DHS), a ChIP-seq transcription factor (TF) binding site as well as 
being at a critical nucleotide of this TF motif signature which makes this SNP much 
more promising functional candidate. SNP 4 only associates with a DNaseI 
hypersensitive site while SNP 3 is also in a cis-eQTL for a given gene. Thus if we 
were to follow systematic approach we could prioritize polymorphisms in this region 
from the ‘most functional’ to ‘least functional’. As in this example, Schaub et al. report 
that in the majority of associations the SNP most strongly supported by functional 
annotation is not the sentinel SNP from GWAS but a SNP in LD with the sentinel 
SNP (Schaub et al., 2012).  
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Figure 5: Combining GWAS-associated locus with human genome regulatory annotation. Reproduced 
with permission from Schaub et al. (2012). 
 
There are numerous possible regulatory features and patterns of gene regulation 
which are both cell type specific and can vary at different stages of development. 
Here, we briefly explain the features that can be considered for overlapping with 
GWAS loci and the possible underlying biological mechanisms that may be 
responsible for some of these. Because patterns of gene expression are cell type 
specific and highly dependent on the context, annotation of regulatory elements will 
vary between cell types. Therefore it is important to use those annotations that were 
generated in the cell types relevant for the phenotype of interest. We discuss the 
issue of choosing the relevant cell types in the in vitro approaches section. In Table 7 
we summarize some of the available on-line sources that contain datasets relevant 
for the respiratory research community. 
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Table 7: Online human genome regulatory information dataset resources relevant for respiratory 
research 
Source Cell type Example 
Datasets 
Website 
ENCODE 
project 
Human 
Airway 
Epithelial 
Cells 
rRNA-depleted 
RNAseq  
https://www.encodeproject.org/experiments/ENCSR822SUG/  
ENCODE 
project 
Human 
Airway 
Epithelial 
Cells 
DNase-seq on 
human NHBE 
treated with 6uM 
retinoic acid for 
48 hours 
https://www.encodeproject.org/experiments/ENCSR000EPN/  
ENCODE 
project 
Human 
Airway 
Epithelial 
Cells 
H3K27me3, 
H3K4me3, 
H3K36me3, 
CTCF     
ChIP-seq 
 
DNaseI-seq 
https://www.encodeproject.org/biosamples/ENCBS417ENC/  
NIH 
Epigenome 
Project 
Adult Lung  Bisulfite-Seq, 
mRNA-Seq, 
H3K36me3, 
H3K4me1, 
H3K4me3, 
H3K9me3, 
H3K27ac 
ChIP-seq 
http://www.roadmapepigenomics.org/data/tables/adult  
NIH 
Epigenome 
Project 
Foetal Lung H3K27me3, 
H3K4me1, 
H3K36me3, 
H3K4me3, 
H3K9ac, 
H3K9me3, 
ChIP-seq 
 
DNaseI-seq 
http://www.roadmapepigenomics.org/data/tables/fetal  
ENCODE: ENCyclopaedia Of DNA Elements (Consortium, 2004). NIH: National Institutes of Health. 
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Transcription Factor (TF) binding sites   
The definition of a TF is a protein that binds to genomic DNA in a sequence-specific 
manner and controls the rate of gene transcription (Latchman, 1997). TFs can act 
either individually or as cofactors to promote or repress recruitment of RNA 
polymerase to specific genes, thus acting as an activator or suppressor of gene 
expression (T. I. Lee & Young, 2000). A critical characteristic of TFs is that they 
contain a DNA-binding domain which mediates the binding of TF to its cognate 
sequences (Ptashne & Gann, 1997).  
The current method of choice to identify TF binding sites is ChIP-seq (Adli & 
Bernstein, 2011). In ChIP-seq proteins are captured while attached to DNA by cross-
linking with formaldehyde and the TF is immunoprecipitated using a specific 
antibody. DNA is purified from precipitated protein and sequenced by the shotgun 
approach using next-generation sequencing (NGS). Reads are then aligned to the 
reference genome and from then on sequence reads are called sequence tags. An 
enrichment of tag density over a particular region suggests that particular site to be 
the binding site of the TF. Mock immunoprecipitation using non-specific antibody 
may be used as a control in ChIP-seq experiments however the current 
recommendation of the ENCODE consortium is to use ‘input control’ instead. Input 
control is a sequenced DNA without immunoprecipitation to account for local read 
distribution biases (Landt et al., 2012). Demonstrating the specificity of antibody is 
pivotal and can be validated by either western blotting (WB) upon protein lysate or 
immunofluorescence (IF) combined with RNAi-mediated knockdown in cells (Landt 
et al., 2012). Several computational approaches have been devised to analyse 
ChIPseq data, the most popular of which are Model-based Analysis (MACS) (Zhang 
et al., 2008), Spatial Clustering for Identification of ChIP-Enriched Regions (SICER) 
(Xu, Grullon, Ge, & Peng, 2014) and HOMER (Heinz et al., 2010) toolkits. However, 
many more programmes have been devised for ChIPseq analyses, an excellent 
overview of which has been published by Bailey et al. (Bailey et al., 2013).  
For a given GWAS signal locus, a TF binding onto a SNP variant is highly indicative 
of this variant being functional. Schaub et al. has shown that TF binding (as 
demonstrated by ChIP-seq) is the most enriched functional element in GWAS loci 
when compared to the rest of investigated regulatory elements (Schaub et al., 2012). 
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This finding is highly indicative of the complex nature of phenotypes that were thus 
far studied by GWAS. One possible scenario for a mechanism behind the genetic 
association signal is that the causative variant is controlling the expression of the 
nearby gene which encodes a TF (Figure 6). Different levels of TF in turn affect the 
expression of TF’s regulome (i.e. the set of genes regulated by the TF) which 
contains genes belonging to molecular pathways important for the investigated 
phenotype. It is important to bear in mind that these hypotheses can be only 
considered preliminary and would require experimental validation with respect to 
genetic loci associated respiratory phenotype.    
Figure 6: One possible mechanism driving a genetic association signal via TF activity. Reproduced with 
permission from Knight (2014).  
 
 
Post-translational histone tail modifications 
Mapping of histone tail modifications and incorporating them onto GWAS loci is 
another in silico approach that can be used to help with the interpretation of non-
coding variants. Establishing histone modification sites is similar to establishing TF 
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binding sites. Antibodies specific for various kinds of histone modifications are used 
for ChIP-seq analyses. Post-translational histone tail modifications such as histone 
3, lysine 4 trimethylation (H3K4me3), H3K27me3, or H3K36me3 act as epigenetic 
signals regulating gene expression and chromatin modelling (Bannister & 
Kouzarides, 2011). Thus these modifications act in epigenetic control of gene 
expression and associate with different gene activities. For example, H3K4me3 
tends to highlight actively transcribed loci while H3K27me3 associates with the 
silenced X-chromosome in females (Gibney & Nolan, 2010). Histone modifications 
are also used to identify the location of other functional elements such as enhancers 
(Shlyueva, Stampfel, & Stark, 2014). The above list is not exhaustive of all possible 
histone modifications and a detailed description of the majority of known histone 
modifications can be found reviewed in (Bannister & Kouzarides, 2011). Because the 
majority of SNPs in GWAS studies are non-coding and aberrant gene regulation is 
thought to play a predominant role in disease pathogenesis, epigenetic control is 
likely to take a central stage in functional translation of GWAS findings. For example, 
patients with genetic susceptibility for COPD may have the predisposition for low 
lung function due to a developmental defect. Epigenetic mechanisms were shown to 
play a central role in early embryological development and organogenesis (Kiefer, 
2007). Therefore aberrant resetting of epigenetic marks could be due to 
inappropriate expression levels of epigenetic effector molecules. As is the case for 
other regulatory elements, patterns of histone modifications vary depending on cell 
type. Hence, again, the investigator is advised to use datasets from tissues relevant 
for the phenotype of interest.  
Other regulatory elements 
DHSs are locations of regulatory DNA based on NGS of genomic DNA sensitive to 
cleavage by DNaseI. These sites mark the accessible chromatin and overlay the 
majority of known regulatory elements including promoters, enhancers, silencers, 
insulators and imprint control locus regions. DHSs show evidence of recent 
functional evolutionary constraint. Interestingly, DHS in pluripotent and immortalised 
cells show higher mutation rates than that observed in highly differentiated cells 
(Thurman et al., 2012). Genomic sequences showing conservation of DNA across 
the species are likely to be functional. Although approximately only 1.5% of the 
genome is protein coding, about 8.2% is under purifying selection and hence likely to 
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be directly functional (Rands, Meader, Ponting, & Lunter, 2014). Genome-wide DNA 
methylation profiling through bisulfite conversion followed by NGS is another high 
throughput approach to detect a mark important in regulation of gene expression (Y. 
Li & Tollefsbol, 2011). The effects of DNA methylation are context dependent but 
they generally associate with silencing of genes in cis, especially if it relates to the 
methylation status at the CpG islands (Deaton & Bird, 2011). Finally, regions 
associated with short and long non-coding RNA involved in diverse regulatory roles 
can be identified through RNA sequencing (RNAseq) where a cDNA library is 
prepared with a ribosomal RNA depletion protocol. Public availability of datasets 
allows for functional annotation of the human genome enabling the prioritization of 
genes or SNPs in GWAS loci and testable hypothesis generation.  
A very useful on-line tool for rapid preliminary examinations of candidate GWAS loci 
is the Broad Institute’s HaploReg (Ward & Kellis, 2012). This software allows for the 
exploration of annotations of the genome at particular variants representing 
haplotype blocks. Information on haplotype blocks is based on the 1000 Genomes 
Project (Genomes Project et al., 2012). Linked SNPs can be visualized along with 
sequence conservation, chromatin annotation from the ENCODE and Roadmap 
Epigenomics projects, the effect of SNPs on gene expression from eQTL studies, as 
well as the effect of SNPs upon putative regulatory motifs. To illustrate this approach 
we have investigated sentinel SNP rs10516526 on 4q24 identified as associated with 
FEV1 in SpiroMeta (Table 3) using HaploReg (Figure 7). It is apparent using the 
conservative r2=0.8 that this SNP is in LD with a large number of potentially 
functional SNPs (Figure 7).  
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Figure 7: HaploReg output for sentinel SNP rs10516526 identified as associated with FEV1 in SpiroMeta. 
 
An in silico case study: regulatory features at 4q24 locus 
The identification of the regulatory features within the GSTCD/INTS12 locus on 4q24 
has been used to provide further insight into the possible regulation of gene 
expression in this lung function associated locus (Obeidat et al., 2013). This 
approach identified a possibly shared promoter region for the INTS12 and GSTCD 
genes with evidence of H3K27 acetylation (Ac) histone mark, DNase 
hypersensitivity, transcription factor binding and CpG islands detected in-between 
the oppositely transcribed genes (Figure 8). This finding led to the hypothesis of 
coordinated expression of these genes which was observed in a range of airway 
structural cells and lung tissue (Figure 7). However, although SNPs within this 
putative regulatory region were predictive of INTS12 expression this was not 
observed for GSTCD suggesting there may be some gene specific effects. Finally, it 
is important to bear in mind that the regulatory features found enriched at the 
putative regulatory region were generated in cell lines that were not derived from 
lung-relevant cells (Obeidat et al., 2013).   
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Figure 8: Regulatory features within the GSTCD/INTS12 locus on 4q24. A: The GSTCD/INTS12 locus is 
shown, annotated with RNA sequencing, H3K27Ac histone marks, DNase hypersensitivity, transcription 
factor binding and CpG islands (UCSC Genome Browser (http://genome.ucsc.edu/)) on the Human Feb 
2009 (GRCh37/hg19) assembly. For the H3K27Ac histone marks and RNA sequence tracks, peak height is 
proportional to signal amplitude, with colours representing datasets in different cell backgrounds (pale 
blue H3K27Ac histone trace = human umbilical vein endothelial cell (HUVEC); blue/grey = K562 
erythroleukaemia cells). For the DNase hypersensitivity and transcription factor binding tracks, a grey 
band indicates the extent of the hypersensitive region and the intensity of the band is proportional to the 
maximum signal strength observed in any cell line.  
B: Expression of GSTCD and INTS12 mRNA in Lung and Airway cells. mRNA expression in human airway 
smooth muscle (HASM) cells, human bronchial epithelial cells (HBEC) and peripheral blood mononuclear 
cells (PBMC) is shown relative to mRNA from lung. Open bars depict GSTCD expression whereas black 
bars show INTS12 expression. Values shown are mean and standard error of the mean (SEM) (n=3). Only 
the expression of GSTCD in HBEC relative to lung was statistically significant (P<0.05).  
C: Correlation between GSTCD and INTS12 ΔCt values in HASM, HBEC, PBMC and lung. The correlation 
coefficient between these measures was r=0.8, P<0.0001. Adapted with permission from Obeidat et al. 
2013. 
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More advanced approaches: Unbiased analyses of genomic feature overlaps 
between GWA data and regulatory data 
It should be noted that a large degree of non-functional overlap between GWAS loci 
and functional elements can be anticipated. Therefore, it is important to use an 
unbiased approach when investigating intersections to determine which overlaps are 
potentially functional and which overlaps are expected by chance. Several different 
bioinformatic approaches have been developed to assess the significance of 
overlaps.  
Statistical tests (e.g. Fisher’s exact test) have traditionally been used to test the 
overlap between two regions. In Fisher’s test the number of overlaps and number of 
intervals unique to each feature are calculated and the test of significance is 
performed given the intervals coverage and the genome size. It is implemented in 
BEDtools suite for analysis of NGS data (Quinlan & Hall, 2010). On the other hand, 
the Jaccord statistic is implemented in (Favorov et al., 2012) and it measures the 
ratio of the number of intersecting base pairs between two regions to the number of 
base pairs in the union of these regions. Therefore it is a good measure if we expect 
one set of regions to be within another set of regions. The final statistic ranges from 
0 to 1, where 0 represents no overlap and 1 represents complete overlap. Jaccord’s 
statistic is also used in BEDtools (Quinlan & Hall, 2010). Permutation-based 
approaches take reference and test regions as input and calculates the observed 
number of overlaps between the reference and test. Test regions are then assigned 
to random regions with the possibility of masking certain parts, such as non-
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mappable repetitive regions of the human genome. The number of overlaps between 
shuffled test regions and reference are re-calculated multiple times and the 
distribution of random overlaps are compared to the observed (Diez-Villanueva, 
Mallona, & Peinado, 2015). The Genomic Association Test (GAT) is another tool and 
uses a null model that the two sets of intervals are placed independently of one 
another. Similarly to the permutation-based approaches, the statistical significance is 
based on simulation (Heger, Webber, Goodson, Ponting, & Lunter, 2013). 
Quantitative Trait Loci (QTL) Approaches: expression QTL, splicing QTL, 
protein QTL and allele-specific expression 
The identification of SNPs as eQTL, splicing QTL (sQTL) (Majewski & Pastinen, 
2011), or protein expression QTL (pQTL) raises the possibility of those SNPs being 
functionally relevant and potentially causative. The most commonly used approach is 
to study transcript eQTLs where different human primary cells, cell lines or tissue 
have been characterised for both mRNA transcript expression and have been 
genotyped on GWA platforms. To date, eQTL studies have relied on microarray 
based technology with common microarrays utilizing probes located at the 3’UTR 
regions in order to target areas common to all annotated gene isoforms. On the other 
hand, exon arrays were designed by implementing probes targeting individual exons 
(Majewski & Pastinen, 2011). Exon array datasets can be noisy due to short probe 
design and probe hybridization signal saturation and hence have various analytical 
challenges (Kwan et al., 2008). Resolution at a splicing level has been achieved by 
custom arrays targeting splice-junctions (Calarco et al., 2007). Nevertheless, 
because of limitations of a priori gene annotation knowledge as well as complexity of 
design and analysis, microarrays are gradually being replaced by RNAseq 
technology (Majewski & Pastinen, 2011). RNAseq provides more accurate 
estimation of known or unknown transcript abundance and in a larger dynamic range 
(Z. Wang, Gerstein, & Snyder, 2009).  
eQTL analyses particularly reinforce the notion that the observed association signal 
relates to the expression of either near-by (cis-QTLs) or distant (trans-QTLs) genes 
(Figure 9). Although these variants are sometimes said to ‘control’ the gene 
expression, the QTL SNP may not be controlling these outcomes but rather be in LD 
with the truly functional SNP. Nevertheless, mapping gene expression as a QTL trait 
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is a powerful way to identify markers correlated with differential gene expression at a 
population level (Rockman & Kruglyak, 2006) and can prioritize SNPs or genes in 
GWAS loci. Studies have now established that the SNPs identified in GWAS of 
human traits are enriched for eQTL SNPs (Hao et al., 2012; X. Li et al., 2015; Luo et 
al., 2015; Schaub et al., 2012). 
Figure 9: An illustrative hypothetical example of the cis-eQTL and trans-eQTL together with their 
associated per-genotype gene’s read counts. On the left hand side we can see the example of cis-eQTL 
where allele C associate with low gene expression while allele G associates with high gene expression. A 
heterozygous individual with both alleles is showing allele-specific expression (ASE). On the right hand 
side we can see the example of trans-eQTL where allele T associate with low gene expression while allele 
A associates with high gene expression. In contrast to cis-eQTL, trans-eQTL is not showing ASE in a 
heterozygous individual. Note that total per gene read counts cannot distinguish between ASE and non-
ASE as reads have to be split depending on what paternal chromosome they align to. Adapted with 
permission from (Sun & Hu, 2013). 
 
eQTL mapping can be particularly useful for identifying potential candidate genes 
contained within a broad association region. For example, our research group 
prioritized genes at locus 4q24 previously associated with the lung function measure 
FEV1 and risk of COPD by identifying eQTL SNPs in a range of datasets generated 
in lymphoblastoid cell line, liver and brain tissue (Obeidat et al., 2013). INTS12 is 
39 
 
amongst three gene candidates at this locus and was the only gene to have cis-
eQTL with 4q24 SNPs in different cell types making this candidate gene likely to 
harbour genetic variation driving the association signal for lung function. These eQTL 
datasets have now been superseded and from a respiratory perspective excellent 
additional resources exist including lung tissue (Hao et al., 2012; Obeidat et al., 
2015), blood cells (Westra et al., 2013) and airway epithelial cells (X. Li et al., 2015; 
Luo et al., 2015). The diversity of human tissues and cells and cohort sizes with 
eQTL data available will continue to expand. 
Splicing QTL and Allele Specific Expression 
Combining the population genotype or genome sequence data together with 
RNAseq-derived gene expression can allow for identification of not only eQTLs but 
also sQTLs. Mapping the RNAseq reads to the reference genome followed by 
counting the number of allele-specific reads that overlap with a heterozygous SNP 
allows detection of allele-specific expression (ASE) (Figure 10). The ability to detect 
ASE is a unique feature of RNA-seq which is not possible to infer using microarrays. 
There are major technical challenges in the reliable measurement of ASE and 
developed methods for the determination of ASE in RNAseq data have been 
reviewed extensively by Sun and Hu (Sun & Hu, 2013).  
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Figure 10: An example of allele-specific expression (ASE). Instead of counting total reads per gene, in 
determination of ASE, exonic (therefore sequenced) SNPs are imputed with not transcribed target 
(genotyped) SNP and read counts are performed per haplotype. Difference in read count between the 
haplotype, as is the case for individual 1, is indicative of ASE. Reproduced by permission from (Sun & 
Hu, 2013).  
 
In silico approach case studies: eQTL enrichment at respiratory loci 
A very recent study by Obeidat et al. (Obeidat et al., 2015) utilised the lung tissue 
eQTL dataset (n=1,111) from Hao et al. to investigate the genetic association signals 
identified in the SpiroMeta-Charge GWAS meta-analyses of both FEV1 and 
FEV1/FVC (Hancock et al., 2010; Hao et al., 2012; Luo et al., 2015; Repapi et al., 
2010; Soler ArtigasLoth, et al., 2011). This study compared 468,300 cis and 16,677 
trans-eQTL SNPs identified in the lung with the 2,419,122 SNPs interrogated in the 
SpiroMeta-Charge consortium papers. The analyses identified a significant 
enrichment for both cis and trans eQTL variants. More specifically, for the 6615 
SNPs identified as associated with FEV1, 3413 were also cis-eQTL SNPs (52%) 
giving a 2.7 fold enrichment (Obeidat et al., 2015). Using a similar approach for 
FEV1, there was also an enrichment for trans-eQTL SNPs of 37.9%. Similarly, for the 
FEV1/FVC associated SNPs there was enrichment for both cis-eQTL (2.2 fold 
enrichment) and trans-eQTL (12.6 fold enrichment) SNPs (Obeidat et al., 2015). 
More importantly, the identification of gene transcripts that the associated SNPs in 
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each region regulated was identified providing greater insight into the potential genes 
underlying the association signal (Obeidat et al., 2015).  
 
Protein eQTL can provide novel insight beyond cis and trans mRNA eQTL 
While eQTL analyses based on mRNA quantification can provide valuable 
information regarding the functional effect of SNPs and haplotypes, these analyses 
exclude the role SNPs may play in regulating post transcriptional mechanisms that 
may also be relevant.  A good example is the recent protein eQTL analyses of serum 
urokinase plasminogen activator receptor (suPAR) levels (Portelli et al., 2014). uPAR 
has been identified as an asthma susceptibility gene (Barton et al., 2009) and has 
been shown to be differentially expressed in the airways (Stewart, Nijmeh, Brightling, 
& Sayers, 2012) and blood (Portelli et al., 2014) in asthma patients. The receptor 
exists as a glycosyl-phosphatidylinositol (GPI)-linked receptor and is involved in a 
wide range of functions including migration, proliferation and adhesion and is also 
involved in fibrinolysis (Portelli et al., 2014). Importantly, the receptor exists as both a 
soluble form generated by splicing and a soluble form generated by cleavage and 
these soluble forms are thought to be involved in regulating overall receptor function 
(Stewart & Sayers, 2009). In the protein eQTL analyses, the cleaved form of suPAR 
was quantified in the serum of 96 control and 512 asthma subjects and a GWAS 
completed using this as a quantitative trait. This approach identified a key SNP 
present in the promoter of human plasma kallikrein gene (KLKB1) as a determinant 
of suPAR protein levels, and subsequent biochemical analyses demonstrated that 
this SNP was an eQTL for KLKB1. We were able to show that KLKB1 subsequently 
cleaves uPAR from the surface of the cell providing a regulatory genetic post-
translational mechanism (Portelli et al., 2014). This study, using a protein eQTL 
approach, therefore identified a novel way whereby an asthma susceptibility gene 
can be modified by a genetically driven post-translational mechanism. 
In summary, in silico approaches to facilitate the translation of genetic association 
analyses can be invaluable to provide both variant and gene specific information 
regarding the regulation in these loci. This approach can be effectively used to 
generate novel hypotheses about the potential genes or variants contributing to the 
phenotypic variation but alone they do not constitute enough evidence. Ultimately 
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these hypotheses ought to be validated in in vivo and in vitro models. Candidate 
regulatory variants, identified through overlap with publically available functional 
element annotations as described require experimental testing using a diverse range 
of methods in order to have confidence in the observed effects.    
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In vivo methods to translate GWAS findings 
Establishing an expression profile of specific genes in the human adult lung 
Once a potentially causative gene has been identified, it is essential that the 
expression profile for this gene, at both mRNA and protein levels, is established in 
relevant human tissue. Analysing expression at cellular and subcellular levels may 
provide evidence of gene function and additional insight can be derived by 
comparing expression between healthy and disease states and during different 
developmental stages 
Immunohistochemisty (IHC) is a widely used tool to characterize protein expression 
in human tissues. In addition to providing information on protein localization within 
cells (nuclear, cytoplasm and/or membranous), IHC can be utilized to assess the 
level of protein expression based on staining intensity. The human protein atlas, a 
publically available database, encompasses the protein expression of 44 normal 
human tissues (www.proteinatlas.org, (Uhlen et al., 2005)). To better understand the 
role of lung function associated genes within the lungs, genes encoding protein can 
be interrogated for their expression profile in a range of human tissue including the 
lung shown on the protein atlas. Each antibody has been highly optimized and tested 
on many of the 44 tissues. For example, lung function associated gene GSTCD, was 
shown to have variable protein expression across multiple human tissues, with little 
or no staining in the central nervous system and high expression in the male 
reproductive system, urinary and gastro-intestinal (GI) tracts, liver and pancreas. 
Specifically in the lung, GSTCD had moderate membranous and cytoplasmic 
immunopositivity in the bronchial epithelium and lung macrophages, however 
expression was absent in pneumocytes (Figure 11). Another lung function 
associated gene at 4q24, INTS12, was highly expressed in the nuclei of the majority 
of tissues. We found moderate protein expression in pneumoctyes and macrophages 
of the lung whilst the bronchial epithelium was highly immunopositive (Figure 11). 
This staining pattern in multiple cell types potentially confirms the role as a regulator 
of RNA processing and/or other functions in the nucleus and implies INTS12 function 
may be crucial in many cell types (Obeidat et al., 2013). Similarly, another lung 
function associated gene HTR4 (5q33) was found to be highly expressed in the GI 
tract and neuronal cells of the central nervous system and cerebellum of the brain. In 
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the lung, bronchial epithelial cells were moderately immunopositive in the cytoplasm 
and membrane (Hodge et al., 2013). HTR4 protein expression was absent in the 
pneumocytes and macrophages.  Thus, the different patterns of expression of genes 
identified by GWAS may give clues about function where this not already defined.  
In addition to identifying protein expression in normal human tissues of lung function 
associated genes, it is important to consider whether protein expression changes in 
disease. The key questions here are: does protein expression increase or decrease 
and can the change in expression be used as a potential biological or prognostic 
marker? Again, as an example, our previous studies have shown no significant 
change in the protein expression of GSTCD and INTS12 in the small numbers of 
normal and COPD lung tissues tested to date (Figure 11).  
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Figure 11: GSTCD and INTS12 protein expression in human tissue.  Immunohistochemical studies 
assessed GSTCD and INTS12 protein expression in tissue sections from controls and individuals with 
COPD. All images x40 magnification. A: Representative images of GSTCD expression in lung tissue from 
three healthy donors (images a and e) with matched isotype controls (iso, images c and g) and in lung 
tissue from three donors with COPD (images b and f) with matched isotype controls (iso, images d and 
h). B: Representative images of INTS12 expression in lung tissue from three control donors (images a 
and e) with matched isotype controls (iso, images c and g) and in lung tissue from three donors with 
COPD (images b and f) with matched isotype controls (iso, images d and h). Reproduced with permission 
from (Obeidat et al., 2013). 
 
 
There are a range of other in vitro models to study human lung tissue, the most 
obvious being primary cell culture which has widely been used to look at responses 
in structural cells: these models are discussed later in the review,  The biggest 
problem with these models is the lack of context, as typically these are cultures of a 
single cell type.  To get around this issue, other approaches have been developed 
including the use of (i) the human lung explant model and (ii) the human precision 
cut lung slice (PCLS) model (Hackett, Holloway, Holgate, & Warner, 2008; Wohlsen 
et al., 2003). The human lung explant model can be used for a wide range of 
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applications including the identification of regulatory mechanisms defining the 
expression profile of specific or global gene expression e.g. in the presence of 
environmental triggers such as cigarette smoke, or infection such as respiratory 
syncytial virus. In the PCLS model, fresh lung tissue is thinly sliced and bronchial 
contractions can be measured in normal and diseased human lung in the presence 
and absence of stimuli or drugs which can provide insight into the role of specific 
genes or sets of genes in airway contraction.  
Defining a role for lung function associated genes in human lung development 
Data from the lung function GWAS meta-analyses suggest many of the identified 
genes may be of importance in foetal or early life lung development as the majority 
of the associations were still present when these analyses were restricted to the 
paediatric cohorts (Repapi et al., 2010). It is therefore important to question whether 
spatial or temporal expression of these genes early in human life and/or throughout 
childhood may be related to or predict lung function and disease later in adult life..  
Lung development has five in utero stages, with development continuing post-
natally. Organogenesis occurs during the first two stages of lung development, 
Embryonic and Pseudoglandular. During the Embryonic stage of lung development 
(4-8 weeks) formation of the major airways occurs with the lung primordium (~day 
30) subdividing into the two main bronchi (~day 33). The trachea and bronchi 
continue to develop and the pulmonary vein and artery are also formed by this time. 
Lung buds differentiate from each bronchi into the pseudoglandular stage of 
development (6-17 weeks). Terminal bronchioles, neural networks and blood vessel 
continue to develop producing conducting airways. By the end of the 
Pseudoglandular stage, pneumocyte precursors are present as an epithelium. 
During the Canalicular, Saccular and Alveolar stages of development, rapid 
differentiation occurs. At the Canalicular stage of development, respiratory 
bronchioles are formed and Type II pneumoctyes differentiate into Type I 
pneumocytes. Surfactant is produced by Type I pneumocytes from the 25th week 
post conception. The level of surfactant increases until birth. At the Saccular stage, 
the air spaces expand and alveolar ducts are formed. At the Alveolar stage, alveolar 
sacs are formed through secondary septation and alveolarization which continues 
after birth up to around 8 years of age with the generation of new, and growth of 
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existing alveoli. Lung volume continues to increase with skeletal growth, and reaches 
a maximum between 25 and 35 years of age. 
Apart from genes with prior evidence for a role in human development e.g. PTCH1 
and HHIP of the hedgehog signalling pathway, little is known about the role and 
expression of lung function associated genes during lung development (Bellusci et 
al., 1997; L. A. Miller et al., 2004; Pepicelli, Lewis, & McMahon, 1998). The gene 
expression omnibus (GEO) is a publically available resource containing large 
datasets which can be used by the scientific community. We have previously utilized 
a gene expression microarray dataset (Kho et al., 2010; Melen et al., 2011) of 38 
foetal lung samples analyzed using Affymetrix U133 Plus 2 arrays to assess whether 
the expression of key genes is altered during normal human lung development 
(Hodge et al., 2013; Obeidat et al., 2013). The 38 samples analysed contained 27 
lungs from the pseudoglandular stage (specifically 7-16 weeks) and 11 from the 
canalicular (17-26 weeks) stage of lung development. As an example, we were able 
to show that whilst INTS12 expression did not change throughout the development 
of the lungs, GSTCD mRNA expression significantly decreased and HTR4 
expression increased with rising foetal age throughout the Pseudoglandular and 
Canalicular stages (Table 8).  
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Table 8: Fetal lung gene array data for INTS12, GSTCD and HTR4 expression during Pseudoglandular and 
Canalicular stages of lung development. Adapted with permission from (Hodge et al., 2013; Obeidat et al., 
2013). 
Gene 
name 
Probe ID Average 
expression 
t P value Adjusted 
P value 
β correlation Significant 
effect 
INTS12 218616_at 8.2248 -1.7318 0.0911 0.2096 -0.0040 n/s 
GSTCD 220063_at 5.6144 -2.3059 0.0265 0.0862 -0.0037 n/s 
GSTCD 1554518_at 5.8000 -3.2205 0.0026 0.0150 -0.0055 Decreased 
expression 
with age 
GSTCD 241126_at 3.4619 1.0242 0.3120 0.4878 0.0012 n/s 
GSTCD 235387_at 6.3236 -4.4776 0.0001 0.0009 -0.0115 Decreased 
expression 
with age 
HTR4 216939_s_at 3.2999 0.9672 0.3393 0.5156 0.0009 n/s 
HTR4 207577_at 3.6986 3.3242 0.0019 0.0121 0.0024 Increased 
expression 
with age 
HTR4 207578_s_at 7.0472 0.3855 0.7020 0.8160 0.0008 n/s 
Table amalgamated from (Hodge et al., 2013; Obeidat et al., 2013). Probe ID: Affymetrix U133 Plus 2 expression array probe ID; Average 
expression: across all samples; t: t-statistic describing differential expression; P value: unadjusted P value; adjusted P value: controlling for false 
discovery rate; β coefficient: log-odds ratio (corresponding to the mean change in gene expression per day during the studied period, 7-22 weeks 
of gestational age); n/s: no significance observed. 
Interestingly, we have recently identified that 29 of the lung function associated 
genes identified by GWAS meta-analyses (Hancock et al., 2010; Loth et al., 2014; 
Obeidat et al., 2011; Repapi et al., 2010; Soler ArtigasLoth, et al., 2011) were 
differentially expressed during lung development at the mRNA level (Miller, S. 
unpublished data).  
The Human Developmental Biology Resource (http://www.hdbr.org/) is an excellent 
additional source of human embryonic and foetal tissue samples within the UK with 
samples ranging from 3 – 20 weeks post-conception. In previous studies we have 
utilized this resource to aid the immunohistochemical assessments of lung function 
associated genes as an approach to try and reconcile differential expression we 
have observed at the mRNA level with protein expression data. Again, using 
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GSTCD, INTS12 and HTR4 as examples, by studying 12 samples between 19 days 
and 19 weeks post conception (6 Embryonic, 4 Pseudoglandular and 2 Canalicular 
stage lungs) we were able to see different patterns of protein expression. GSTCD 
protein expression showed a trend towards a decrease in protein expression from 
the Pseudoglandular to Canalicular stage (Figure 12a). Overall, INTS12 expression 
remained consistent throughout the 3 developmental stages studied and was 
localised to the nucleus in most airway cell types in keeping with the work described 
above on adult lung (Figure 12b). On the contrary, HTR4 expression increased from 
low in the early Embryonic lungs to high during the pseudoglandular stage and lower 
again in the subsequent Canalicular stage samples tested (Figure 12c).  
Figure 12: GSTCD, INTS12 and HTR4 expression in the developing lung. (a) GSTCD expression in tissue 
from human foetuses at a range of developmental stages: embryonic (19 days, a and b; 21 days, c and d; 
23 days, e and f); pseudoglandular (10 weeks, g and h; 12 weeks, i and j); canalicular (17 weeks, k; 19 
weeks, l). Expression was observed to be increased through the pseudoglandular stage. (b) INTS12 and 
(c) HTR4 expression in the same panel of tissue samples as described above. Isotype controls were all 
negative (data not shown). Figures reproduced from (Hodge et al., 2013; Obeidat et al., 2013). 
Figure 10a: GSTCD expression in the developing human lung. 
 
Figure 10b: INTS12 expression in the developing human lung. 
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Figure 10c: HTR4 expression in the developing human lung. 
 
Linking the mRNA and protein datasets together, GSTCD mRNA expression 
decreased throughout development which agreed with GSTCD protein expression,. 
INTS12 had a high average mRNA expression of >8 and was not differentially 
expressed during the Pseudoglandular and Canalicular stages of development. This 
was in agreement with the protein expression data which showed either moderate or 
strong INTS12 protein expression in the majority of foetal lung samples. HTR4 
mRNA significantly increased in expression during the studied period which was 
inconsistent with the protein expression data: however. mRNA and protein levels do 
not always correlate well. For instance, miRNAs can regulate post-transcriptional 
gene expression through either gene silencing or targeted degradation and thus 
even though mRNA levels may be high, protein expression could potentially be low 
or absent. As this and other human tissue resources are expanded, we anticipate 
that the ability to interrogate the potential differential expression of candidate genes 
identified in genetic association studies in both foetal, early life and adult human 
tissue will provide unprecedented insight into the potential role of these genes in 
pathways involved in developmental and adult lung homeostasis. However, a major 
limitation of human tissue based approaches is that they are naturally restricted by 
lack of access to longitudinally obtained tissue samples and are often observational 
rather than mechanistic in nature.   This has led to the extensive use of mice to 
define genetic mechanisms and interrogate the roles of specific genes in vivo, 
particularly using transgenic knockout mice.  
Mouse models for respiratory research and the translation of genetic findings 
To functionally characterize genes identified from human lung function GWAS, 
animal models are a useful tool to better understand the role of a given gene within 
the whole organism and the lung in situ (Dawkins & Stockley, 2001). The use of mice 
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in research has always been a controversial issue, and a full understanding of both 
advantages and disadvantages to the study of human health and disease is 
essential. Table 9 highlights the general advantages and disadvantages of the use of 
mice in research. It is interesting to note that although 99% of mouse genes have 
human orthologues, the chromosomal make up in mice is different to humans, with 
mice having 20 pairs of chromosomes rather than 23. Many complex human 
diseases are shared in mice and humans however drug development using pre-
clinical rodent models has been limited in translation success: this is particularly true 
in the respiratory field. A recent review focussed on asthma research highlighted the 
potential over-reliance on animal models as a contributing factor to the lack of new 
drugs coming to the clinic (Edwards, Belvisi, Dahlen, Holgate, & Holmes, 2015).  
Table 9: General advantages and disadvantages of using mice in research. 
Advantages Disadvantages 
1. Fundamental similarity at the gene level 
(95%). 
1. Mice have 20 pairs of chromosomes 
whereas humans have 23 pairs. 
2. Mouse genome sequenced. 
2. Is the use of a mouse to benefit human 
health ethically correct? Some disagree. 
3. Cost effective – breeding, housing and 
maintenance costs are low. 
3. Transgenic mouse rescue can be time-
consuming, labour intensive and costly. 
 
4. Quick research, short lifespan so get results 
soon (One mouse year is 30 human years). 
4. Mice live for 2 years whereas humans live 
~80 years therefore time disparity.   
5. Short generation time. 
5. 15% of gene knockouts are developmentally 
lethal – therefore some studies limited to 
embryonic development. 
6. Many genes involved in complex diseases are 
shared between mice and humans 
6. Mice are not humans and gene function may 
not be the same in such a different organism. 
7. Large litter sizes relative to humans and so 
lots of samples. 
7. Mice have evolved to live in infectious 
environments and are resistant to many 
infections and inflammatory stimuli unlike 
humans. 
8. Can directly manipulate the mouse genome. 
8. Mice are not a higher organism and cannot 
express themselves and so some results rely 
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on the trained animal technicians’ ability. 
9. Inbred strains are well characterised. 
9. Drug treatment in a mouse does not mean it 
will be the same in a human; side effects can 
be different. 
10. Gene knockouts very specific and interferes 
with normal gene expression effectively. 
10. Mice are not in natural environment, lab 
environment is un-natural. 
11. Excellent model to test effects of drugs on. 
11. Research has found responses in mice to 
drugs are dissimilar to that seen in humans 
and also the different organisms have different 
side effects. 
12, Newer approaches to generate genetically 
modified mice such as CRISPR/Cas9 likely to 
speed up mouse transgenic research  
12. Mouse inflammation is dissimilar to human 
inflammation and thus there are limitations on 
the study of inflammatory disease studies (e.g. 
COPD and asthma). 
Respiratory research in the mouse has its own specific considerations. For instance, 
the basic anatomy of mice and humans lungs is not the same, with the pattern of the 
lung lobes and lung branching being significantly different (Table 10). 
Table 10: Specific considerations for the use of mice in respiratory research. 
Advantages Disadvantages 
1. Relatively easy to take non-invasive 
lung function measurements of mice using 
Plethysmographic box. 
1. Lung anatomy differs between mice and 
humans: pulmonary lobulation is dissimilar 
(human right lung has 3 lobes and left has 2 
lobes, whereas mice have a single left lung and 
4 lobes of right lung). 
2.  Challenge experiments possible eg for 
acute lung injury, fibrosis or drug treatment 
2. Humans have extensive cilia whereas mice do 
not.  
3..Possible to sample lung tissue 
whenever required for analysis 
3. Mice have few submucosal glands in trachea 
and no goblet cells which is dissimilar to human 
trachea. 
 4. Mice do not have a cough reflex . 
 5. Differences in bronchial branching, mice have 
6 airway generations whereas humans have 23. 
 6. Mice are obligate nose breathers whereas 
humans breathe through both mouth and nose. 
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 7. Mice do not spontaneously acquire Asthma 
like humans.  
 8. The cellular constituents of mouse and human 
lungs are different. 
 
Despite these considerations it is beyond doubt that the use of mice in basic 
physiology research has provided major advances in the understanding of the role of 
specific genes in mammalian physiology, particular when combined with transgenic 
approaches. In 2011, this area was given a major boost by the formation of The 
International Mouse Phenotyping Consortium (IMPC) which is a world-wide resource 
built from previous programmes including The European Mouse Disease Clinic 
(EUMODIC) and Mouse Genetics Project (MGP), and which has the vision to build a 
comprehensive catalogue of the functions of every gene in the mammalian genome 
(www.mousephenotype.org) (Brown & Moore, 2012). This is to be achieved by the 
generation and extensive phenotyping of ~20,000 knockout mice in a systematic, 
standardized way. Importantly, the embryonic stem cells and knockout mice are 
publically available shortly after their generation and data from the standardized 
phenotype pipeline used to characterise the biological functions of each gene is 
quickly available online (Figure 13).  
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Figure 13: IMPReSS (International Mouse Phenotyping Resource of Standardised Screens) Adult and 
Embryonic Phenotype Pipeline 
 
Baseline data are available through the IPMC on some lung function related genes, 
inclduing INTS12. Mice with INTS12 homozygous knock-out have pre-weaning 
lethality and thus provide evidence that INTS12 has a fundamental role in mouse 
development and health. Additionally, INTS12 heterozygotes were found to have 
increased circulating levels of magnesium. Importantly, the LacZ gene is introduced 
into the gene deletion and therefore can be easily visualised and act as a marker of 
gene expression (Figure 14).  
 
 
 
Figure 14: LacZ expression in INTS12 heterozygote mice characterized as part of the International Mouse 
Phenotyping Consortium (IMPC). 
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As the IMPC expands, more data will become available for GWAS relevant genes 
making this an extremely useful resource. While we have focussed here on IMPC it 
is of course important to note that many transgenic strains of mice have been 
generated way in individual laboratories, including mice with gene deletions for lung 
function associated genes. For example, recent work has focused on gaining insight 
into whether candidate gene HTR4 plays a functional role in pulmonary function 
(House et al., 2015). Knockout of HTR4 resulted in no difference in the histology of 
lungs of HTR4-null mice and wildtype mice. Furthermore, there was no difference in 
the lung volume or body weight of these mice. House et al. hypothesized that 
noncoding variants in HTR4 may exert trans-regulatory effects. They identified that 
HTR4-deficient mice had a higher baseline lung resistance and increased 
methacholine-induced airway hyper-responsiveness (AHR) compared to wild type 
littermates, however these effects were modest. The HTR4-deficient mice were also 
more sensitive to serotonin-induced AHR. Interestingly, challenges with bacterial 
lipopolysaccharide (LPS), bleomycin, which promotes lung fibrosis, and house dust 
mite (HDM) to mimic an asthma phenotype were also performed. The pulmonary 
function and cytokine profiles of HTR4-deficient mice only modestly differed from 
their wild-type counterparts in these models, for example with a reduced IL1 
responses in HTR4-/- following LPS instillation in the lungs (House et al., 2015). 
Thus, the group provided some evidence for a causal relationship between GWAS 
identified HTR4 and pulmonary function, with alterations in baseline lung function 
and increased AHR in HTR4-null mice but no differences in lung histology.  
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Recently, Jin et al. generated a FAM13A-mutant mouse and found the mice to be 
viable and healthy (Jin et al., 2015). As discussed above, SNPS within the FAM13A 
locus have reproducibly been associated with FEV1/FVC. No morphological 
differences were identified in the lungs of FAM13A homozygous mutant mice versus 
littermate WT controls (Jin et al., 2015). Additional experiments suggested that 
FAM13A is involved in Wnt signalling and the authors concluded that under normal 
physiological conditions FAM13A is not an essential gene for developing normal lung 
function.  
One transgenic mouse strain that has dramatically facilitated our translation of 
human GWAS findings is the receptor for advanced glycation end products (RAGE) 
gene deletion mouse. Meta-analyses of GWAS have identified a number of 
polymorphisms in the Advanced Glycation End Product-Specific gene 
(AGER/RAGE) with the pivotal SNP appearing to be in exon 3 rs2070600 (Gly82Ser, 
(C/T)) which is associated with FEV1/FVC (See Table 4). Importantly, this SNP has 
been shown to be a protein eQTL for the soluble form of the receptor in human 
serum (Cheng et al., 2013; Gaens et al., 2009). RAGE deficient mice when exposed 
to cigarette smoke were protected (albeit modestly) from the emphysema like 
phenotype that developed in the lung including airspace enlargement when 
compared to WT littermate controls (Sambamurthy, Leme, Oury, & Shapiro, 2015). 
This protection was at least in part thought to be driven by a reduction in the influx of 
neutrophils into the airways in RAGE-/- mice (Sambamurthy et al., 2015). This study 
therefore shows a key link between a gene associated with lung function and a 
relevant COPD phenotype.  
The use of conditional knockout mice may also be helpful, especially where the 
global knock out is lethal. Currently, the Cre-Lox recombination system is the most 
commonly used organ specific gene knockout technique. LoxP sites are introduced 
around the gene of interest and once in the germline, these mice can be crossed 
with mice containing germline Cre-recombinase. The gene can then be deleted in a 
tissue specific manner. One great advantage of the use of the Cre-Lox system is that 
more mice are viable and survive longer than when a gene is knocked out in the 
whole organism and embryonic or early postnatal lethality can be overcome.  
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Inducible knock out mice can also be produced whereby gene expression can be 
turned on or off by doxycycline or tetracycline-regulated systems (Gunther et al., 
2002; Shockett, Difilippantonio, Hellman, & Schatz, 1995). A way of producing lung 
specific inducible knockout mice is by exploiting the cell make-up of the airways, i.e. 
where Club cells (originally named Clara cells) are exclusively present (Niden, 1967). 
Bertin et al. (and others) have produced transgenic strains of mice whereby the 
expression of Cre recombinase was under the expression of Clara Cell 10kD Protein 
(CC10) (originally (Clara Cell Secretory Protein (CCSP)) and this knockout was thus 
Clara Cell specific (Bertin, Poujeol, Rubera, Poujeol, & Tauc, 2005; H. Li et al., 
2008). The use of other cell specific promoters have also been used; SFTPC 
(Surfactant Protein C (SP-C)) is used to conditionally express genes in the distal 
lung structures (Perl et al., 2005). Although the use of conditional cell-specific gene 
expression systems have many experimental advantages to aid the study of the 
respiratory system, caution is needed and some researchers in the field have 
identified that the expression of the tetracycline-transactivator gene causes 
emphysema-like changes in mice (Sisson et al., 2006), thus identifying a need for 
the careful consideration and use of experimental controls. 
Interestingly, these approaches have been applied to further define the role of RAGE 
in lung homeostasis (Stogsdill et al., 2013). Conditional overexpression of RAGE 
was induced under the control of a human SP-C promoter which should lead to 
enhanced expression in the alveolar epithelial cells. In these mice there was the 
development of an emphysema-like phenotype demonstrating that alterations in 
RAGE homeostasis in adult mice following normal lung development is detrimental 
(Stogsdill et al., 2013). 
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In vitro approaches using human cells to translate GWAS findings 
In the next sections we focus on the use of human model cell systems to further 
define and translate genetic association signals. 
Choosing the cell type to work with 
As discussed above it is important to use cell types relevant to the phenotype of 
interest in order to avoid misleading biological interpretation. Currently available 
regulatory genome annotations have been generated in diverse sets of primary cells 
and immortalized cell lines (Consortium, 2004), each with its advantages and 
disadvantages. In the coming years annotations of un-differentiated and 
differentiated embryonic cells are likely to rise in prominence due to the likely 
developmental basis of many of the traits for which genetic association studies have 
been conducted. Similarly, the use of induced pluripotent stem cells (iPSCs) to re-
generate lineages of differentiated human cells has potential, especially as cells can 
be derived from individuals of known genotype for a region of interest on a known 
genetic background. 
Primary cells are most representative of the human tissues from which they were 
isolated. However, their phenotype is often context specific and there is extensive 
literature that primary human cells when removed from the body may alter in 
phenotype and “dedifferentiate” and so care is needed in interpretation and the use 
of these cells. Isolation of primary cells or precursor stem cells is inevitably more 
challenging than the use of immortalised cell lines. For example obtaining primary 
human bronchial epithelial cells is achieved by bronchoscopy which is invasive for 
the patient and requires local anaesthesia. It is also difficult to obtain a homogenous 
population of cells and this may require additional sorting of cells by fluorescently-
based preparative procedures. In order to have confidence in the cell type used, 
characterization of cells is required. This can be achieved by immunofluorescent 
staining of cell-type specific markers. In general, homogenous primary cell 
preparations are limited in the numbers obtained and in life span but do provide a 
useful tool.  
There are a number of immortalised cell lines which are often used in respiratory 
research. Immortalised cell lines have been well characterized by public consortia. 
Some of these cell lines were shown to retain the properties of the original primary 
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cells from which they were derived (Bocchini et al., 1992), although it is not advisable 
to assume that a cell line has the same gene expression signature as the original 
unmodified cells and this should be examined on a case-by-case basis. Different 
chromosomal re-arrangements, alteration of chromatin, DNA methylation as well as 
histone methylation patterns may be observed in cell lines (Masters, 2000). For 
example we have observed that BEAS2B-R1 cells, which are frequently used as a 
model by those interested in bronchial epithelial cell biology have 68 chromosomes 
(unpublished observation). These transformations may lead to artificial biochemical 
activities and misleading functional genome annotation.. The advantage of cell lines 
is their ease of propagation allowing access to a large numbers of cells for analyses.  
If it is not clear what kind of cell type to utilize, a de novo identification of target cells 
may be applied (Maurano et al., 2012). In this approach annotations from all possibly 
available cell types are systematically integrated into GWAS loci and cell types 
showing prominent enrichment of the considered functional element can be deemed 
relevant for the phenotype of interest. This is a powerful approach if no extensive a 
priori knowledge about the studied phenotype is available. For example, Maurano et 
al. identified IL-17 producing T helper cells as a target cell type for Crohn’s disease 
(Maurano et al., 2012) using this method. This approach can in principle be applied 
to any phenotype for which a genetic association study has been undertaken.  
Investigating non-coding loci 
In addition to the approaches discussed above, there are many in vitro tools which 
can be used by researchers wishing to functionally investigate non-coding candidate 
variants. Of those which have been around for a number of years, luciferase or GFP 
reporter assays can be used for studying transcriptional and post-transcriptional 
gene regulation by directly measuring the functional activity of the controlling 
elements. Causative inferences can then be made by applying mutagenesis to the 
candidate regulatory regions. Electrophoretic Mobility Shift Assays (Hellman & Fried, 
2007). are also often used to screen nuclear extract or DNA sequences for specific 
protein-DNA binding activity.  
The spatial organization of chromosomes: chromosome conformation capture  
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Studying the spatial organization of chromosomes is crucial if we are to understand 
the regulation of gene expression. Because of the epistatic effects of genetic variants 
on the expression of distant genes (Hemani et al., 2014), the emergence of a new 
tool called Capture-C may prove to be useful in elucidating these relationships 
(Hughes et al., 2014). Capture-C is a further development of chromosome 
conformation capture, or 3C, which is used to analyse the organization of 
chromosomes. It utilizes oligonucleotide capture technology (OCT), 3C and high-
throughput sequencing and hence enables researchers to interrogate interactions at 
hundreds of selected loci at high resolution in a single assay. Therefore this method 
can provide mechanistic evidence linking genetic variants to genes. 
This approach has been used to examine the HHIP locus. The GWAS signal at this 
locus was primarily located in the 5’ region of the HHIP gene. This led to the 
hypothesis that the mechanism underlying the association was at least in part due to 
alterations in regulatory mechanisms. Zhou et al. formally tested this hypothesis and 
using a combination of chromosome conformation capture, ChiP-qPCR and reporter 
based assays they identified a long range enhancer in the HHIP gene in the same 
region as the sentinel SNP associated with lung function (X. Zhou et al., 2012). The 
authors went on to further demonstrate that the COPD risk haplotype was associated 
with reduced reporter activity suggesting a causative mechanism leading to reduced 
HHIP expression as observed in lung tissue isolated from COPD patients (Figure 
15).    
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Figure 15: Identification of a long-range enhancer for HHIP in the COPD GWAS locus on chromosome 
4q31. (A) Long-range interaction between the COPD susceptibility locus and the HHIP promoter in Beas-
2B (bronchial epithelial) and MRC5 (lung fibroblast) cells detected by 3C-PCR. The graph demonstrates 
3C interaction frequency of the constant fragment containing the HHIP promoter (orange bar) with other 
target fragments (black bars). The y-axis refers to 3C-PCR products normalized to the interaction 
frequency of fragments from the BAC clone. Geometric means and standard errors were from duplicate 
PCR reactions. (B) The minimal COPD GWAS SNP region (~500 bp around two key SNPs, lightpurple 
column) cloned at forward orientation and reverse orientation showed enhancer activity for the HHIP 
promoter (‘control’, orange) measured by dual-luciferase in Beas-2B cells. (C) The effects of rs1542725 
and rs6537296 were evaluated in the reporter assays. Single-nucleotide alterations were introduced 
individually or combined into minimal enhancer constructs at forward (upper panel) and reverse (lower 
panel) orientations. Adapted with permission from (Zhou et al. 2012) 
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Studying protein coding candidate genes  
With an established candidate protein-coding gene, the traditional assays used for 
the characterization of gene function are gene knockdown using small interfering 
RNA (siRNA) or short hairpin RNA (shRNA) in a range of relevant human cell lines 
and/or primary cells. These methods are particularly useful when little is known 
about the gene function and may be used for hypothesis generation.  For example, 
Portelli et al. have overexpressed the asthma associated gene, urokinase 
plasminogen activator receptor (uPAR) gene (encoding PLAUR protein) in human 
bronchial epithelial cells and observed increased proliferation as a result of this 
manipulation which was suggested to contribute to airway remodelling. (Portelli et 
al., 2014). This fits well with the observation of elevated levels of PLAUR in the 
airway epithelium in asthma patients (Stewart et al., 2012) and association of 
PLAUR levels with worsening prognosis and increased disease aggressiveness in 
other diseases such as cancer and COPD (Ivancso et al., 2013; Smith & Marshall, 
2010). However it is difficult to infer completely the functional role of the gene with an 
overexpression approach and gene depletion is potentially more informative from 
this perspective.  There are commercially available siRNAs  for many of the genes 
jmplicated from GWAS approaches which can be used in cell biology experiments, 
although appropriate controls are essential as off target effects of transfection are 
frequent. 
The in vitro suppression of a specific gene using shRNA followed by global gene 
analyses in human cell lines has provided a novel insight into the role of lung 
function and COPD associated gene HHIP in possible pathway-analysis-inferred 
bronchial epithelial function (J. J. Zhou et al., 2013). In this study, HHIP was targeted 
by shRNA in BEAS-2B airway epithelial cells followed by expression microarray 
analyses identifying 296 differentially expressed genes. Subsequent pathway 
analyses identified a particular enrichment for extracellular matrix proteins and genes 
associated with cell growth providing a potential insight into how HHIP may be 
involved in lung homeostasis. Importantly, a subset of genes were validated using 
additional qPCR in both BEAS-2B and primary human airway epithelial cells and 
shown to be differentially expressed in COPD patient lung samples versus non-
disease controls (J. J. Zhou et al., 2013).    
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Generating novel functional hypotheses through expression profiling and 
pathway analyses 
Although algorithms taking significant GWAS variants as input and pathways likely to 
be affected in the phenotype of interest as output have been developed, these 
algorithms have a relatively limited success in generating hypotheses about the 
biological basis behind considered phenotypes (K. Wang, Li, & Hakonarson, 2010). 
This is largely due to the complex nature of the human genome where various 
epistatic events between alleles are likely to occur. Also, in numerous cases, GWAS 
signals lie within a large region containing no annotated genes. In these situations it 
is often the case that a genetic variant is within an enhancer element and has an 
effect on the expression of a gene distant to its own location. Therefore without the 
understanding of the inter-genomic interactions it is hard to infer what pathways may 
be dysregulated in disease state.   
With candidate genes prioritized it is possible to generate novel hypotheses by 
combining the manipulation of the expression of the gene of interest with global 
transcript expression profiling. For that purpose, RNAseq has advantages that out 
way microarray based approaches, some of which were outlined in the in silico 
section above including greater dynamic range for quantification and the 
investigation of splice variation.  
Having performed a differential gene expression analysis in the presence and 
absence of approaches to target the gene of interest, e.g. RNAi, pathway analysis 
may then be applied. In the classical pathway analysis approach called over-
representation analysis (ORA) the first step requires a creation of an input list of 
genes that are differentially expressed under the considered experimental condition. 
This list of genes is based on an arbitrary chosen statistic of significance such false 
discovery rate below (FDR) 5%. Then, input genes that are part of the pathway are 
counted. This process is repeated using appropriate background of genes (such as 
all protein-coding genes). Lastly, every pathway is tested for over representation in 
the list of input genes using hypergeometric, chi-square or binomial distribution 
(Huang da, Sherman, & Lempicki, 2009). The same principles apply for Gene 
Ontology analyses but instead of counting the number of genes per pathway, genes 
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are counted for cellular process terms. However, the ORA approach is limited in its 
ability to identify biologically-meaningful pathways that vary between experimental 
conditions or phenotypes. Firstly, in ORA genes that are differentially expressed at 
FDR above the statistical threshold of significance, are not included in the analysis, 
and hence this method could miss biologically important genes that do not fulfil the 
criteria of arbitrary decided statistical significance (for example genes that are 
differentially expressed at a P-value <0.051). Secondly, over-represented pathways 
are identified based on gene-counts alone and the analysis does not account for 
quantitative gene expression changes.  
These limitations are addressed by gene set enrichment analysis (GSEA). In 
contrast to ORA, GSEA approach uses all available information regarding gene 
expression and computes an enrichment score for the gene sets based on effect 
size or other ranking statistics. The objective of GSEA is to, given a priori defined 
gene set as well as gene-expression-ranked gene list, determine whether members 
of gene sets are randomly distributed throughout ranked lists, or primarily found at 
the top or bottom of the ranked list (Subramanian et al., 2005). GSEA calculates the 
enrichment score by walking down the ranked list of genes, increasing a running-
sum statistic when a gene is in the gene set and decreasing it when it is not. A 
commonly employed ranking algorithm is a signal-to-noise ranking where mean gene 
expression in one condition is subtracted from the mean expression in the other 
condition divided by the sum of variances. Therefore genes are ranked from most 
upregulated with least conditional variability through genes with moderate changes in 
gene expression at greatest expression variability to most downregulated genes with 
least variability. Hence, in enrichment score calculation, the magnitude of the 
increment depends on the strength of differential gene expression and its biological 
variation. The limitation of GSEA is the assumption that genes and pathways are 
independent from each other, which is not necessarily true considering the 
complexity of cellular networks. Also, because both GSEA and ORA are based on a 
priori defined gene sets, both these approaches are limited by the quality of gene set 
definition. For example, if more than 50% of genes assigned to a particular gene set 
are erroneous then the identified dysregulated pathway will be flawed as well. 
Therefore it is advisable to use the most up-to-date pathway or gene ontology 
definitions that are community curated and adjusted with each new scientific 
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publication. Finally, it is recommended to validate each result with another analysis, 
for instance by testing if the identified dysregulated pathways with one gene 
depletion method agrees with another gene depletion method.       
The analyses mentioned above can help in the prioritization of functional in vitro 
assays that may be performed following the experimental gene expression 
manipulation. This approach is undoubtedly superior to choosing functional read-out 
assays on an arbitrary basis. With evidence of pathway or gene ontology term 
dysregulation, a functional assay related to the discovered dysregulation can be 
performed. For example, with evidence of dysregulation in cellular proliferation 
genes it is worth testing for cell proliferation with one of the available DNA replication 
assays. Having determined gene functions in in vitro models, researchers can further 
hypothesise about possible relationships between phenotype and the identified 
perturbed pathways (Figure 16) 
Figure 16: A workflow of systematic gene function discovery through combination of transcriptomics, 
pathway analysis, hypothesis generation and final biological validation. 
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The promise of genome editing tools 
It has been suggested that the emergence of genome editing is a ‘game changer’ in 
scientists’ attempt to meaningfully translate genetic association findings (Sander & 
Joung, 2014). These methods allow editing any genomic sequence by inserting, 
excluding or modifying sequences in any mammalian cell type or even embryological 
cells to study the effect on model organisms. Importantly, genome editing allows 
simultaneous disruption of a multitude of genes or regulatory elements at once, thus 
allowing the investigation of allele interactions or synergistic effects. This is a huge 
step forward considering the difficulties of achieving this with traditional RNAi-based 
approaches, as well as the polygenic character of the majority of phenotypes. Also, it 
is possible to use these technologies to study the effects of genetic disruptions on 
lineage-specific cellular differentiation. For that purpose, using totipotent or 
pluripotent stem cells (or iPSCs generated via epigenetic reprogramming of mature 
cells) shows great potential promise. It was recently shown that genome editing can 
be used not only to knockout genes but also to induce their expression from 
endogenous promoters (Konermann et al., 2015) or for completely other purposes 
such as modifying epigenetic marks (Gilbert et al., 2013; Maeder et al., 2013; Mali et 
al., 2013). As mentioned, this can be achieved over multiple loci and has the 
advantage of recapitulating the transcription at the endogenous genomic template in 
opposition to recombinant overexpression constructs which may not be 
representative of the endogenous situation. The two most popular genome editing 
techniques are Transcription activator-like effector nucleases, abbreviated as 
TALENs (J. C. Miller et al., 2011), and clustered regularly interspaced short 
palindromic repeats (CRISPR) in association with RNA-guided Cas9 nuclease 
(CRISPR-Cas9 system) (Sander & Joung, 2014). 
TALENs are composed of a nuclease domain fused to a DNA-binding domain. The 
nuclease cleaves the genomic DNA in a non-specific manner but the DNA-binding 
domain confers the needed specificity. This domain is engineer-able to recognize 
specific DNA sequences and essentially has properties similar to transcription 
factors capable of activating gene expression (hence the name transcription 
activator-like effectors molecule). The engineered nuclease binds and causes a 
double-strand break to DNA. Then non-homologous end-joining or homology-
directed repair are activated, thus allowing editing of target sites (Joung & Sander, 
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2013). CRISPR-Cas9 systems are alternative to TALENs and have improved 
cleavage efficiency and eased the implementation at reduced cost. In contrast to 
TALENs, Cas9 nuclease is guided to a target site by a RNA molecule. Therefore, in 
this case, there is no need to design custom proteins for DNA binding. Konermann et 
al. leveraged CRISPR-Cas9 system to induce the expression of multitude of genes 
and this is possible because the entire complex can be provided with distinct effector 
domains such as activator domains, repressor domains or domains altering the 
epigenetic mark (Gilbert et al., 2013; Konermann et al., 2015; Maeder et al., 2013; 
Mali et al., 2013). In those circumstances the Cas9 endonuclease is catalytically 
inactivated (dCas9). These modified CRISPR-Cas9 constructs can be effectively 
used to control the activity of candidate regulatory elements or genes that contain 
significant GWAS signal variants. Introduction into somatic cells can be achieved 
with typical transfection while introduction into model organisms can be 
accomplished with injection into the model organism zygote. As with traditional 
RNAi-based approaches genome editing can occur with off target effects and the 
current challenges are to minimize these to provide more robust interpretation. For 
excellent reviews of TALENs and CRISPR/Cas9 approaches see (Gaj, Gersbach, & 
Barbas, 2013).  
A new avenue in genome editing technology has recently emerged with light-
inducible transcriptional effectors (LITEs) (Konermann et al., 2013). LITE modules 
consist of the light-sensitive photoreceptor cryptochrome 2 (CRY2) that is fused to 
TALEN DNA-binding domain, however, theoretically the concept can be applied to 
the CRISPR-Cas9 system as well (Figure 16). Authors have combined TALEN 
domain, light-sensitive cryptochrome 2 protein CIB1 and its co-partners obtained 
from Arabidobsis in order to induce gene expression by exposure to the light at sites 
determined by specificity of DNA-domain binding. Variable levels of increases in 
mRNA expression were observed (from little to large) and this was accompanied by 
an increase in protein level. The construct allows for reversible modulation of gene 
transcription and epigenetic marks in spatially and temporally sensitive manners via 
the exposure to light (Konermann et al., 2013). This study is essentially a proof of 
concept that overexpression using this unique technique may be possible and it was 
shown to be applicable both in vitro and in vivo. Undoubtedly this new technique 
offers great opportunity for biologists studying gene regulation and gene function in 
68 
 
their genetic translation efforts, however further studies are required to determine the 
specificity of the method and whether it can be used on a routine basis.  
Figure 17: The mechanism of action of light-inducible transcriptional effectors: Light-sensitive CRY2 is 
anchored to DNA-binding TALEN and upon exposure to light recruits CIBI-copartners complex which in 
turn brings transcriptional machinery resulting in expression of nearby gene. Adapted with permission 
from (Konermann et al., 2013)  
 
Exemplary case study: The FTO locus and obesity 
While respiratory genetics translation continues, an exemplary study utilizing many 
of the approaches outlined in this review is the functional characterization of the fat 
mass and obesity-associated (FTO) locus previously associated with obesity 
(Claussnitzer et al., 2015). In this study, Claussnitzer and colleagues initially start 
with a large genomic region on chromosome 16 encompassing the FTO gene 
showing a broad association signal. The initial approach uses a chromatin 
annotation map of the region (from 127 reference epigenomes) which identified an 
unusually long enhancer (12.8 kb) in mesenchymal adipocyte progenitors. This was 
followed by a 10kb-reporter tiling approach encompassing the risk and non-risk 
haplotypes to identify the key genomic region driving haplotype specific enhancer 
activity in the relevant cell type, human SGBS adipocytes (i.e., adipocytes derived 
from a patient with the Simpson–Golabi–Behmel syndrome), which indicated genetic 
control of enhancer activity (Claussnitzer et al., 2015). Chromosome conformation 
capture was then used to identify long range chromatin interactions which included 8 
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genes and importantly developmental regulators IRX3 and IRX5 had genotype-
associated expression. IRX3 and IRX5 were confirmed as being important in obesity 
associated cellular profiles by examining Human Adipocytes (carriers and non-
carriers of the risk haplotype) and by siRNA knockdown. To identify the casual 
variant underlying the risk haplotype promoter-reporter and EMSA approaches were 
used which identified the rs1421085 risk allele within an ARID5B binding site. 
Subsequent, ARID5B knockdown and over-expression modulated IRX3 and IRX5 
expression providing further support for the putative mechanism. Finally, using 
CRISPR-Cas9 genome editing using both risk and non-risk haplotype background to 
introduce the alternative rs1421085 confirmed the effects on IRX3 and IRX5 
expression and importantly determined a developmental shift from browning to 
whitening programs and loss of mitochondrial thermogenesis (Claussnitzer et al., 
2015).    
>can we put the section below in a Text box figure please? 
Inferred biology of selected and most reproducible lung function genes 
In the GWAS for lung function and COPD performed to date, a number of genes are 
reproducibly appearing to be associated with these traits and importantly using 
several of the approaches outlined above look to be the causative genes. Work is 
still being undertaken to both understand what the fundamental biological functions 
of these putative genes are and to elucidate underlying biological mechanisms 
leading to the observed associations. Nevertheless it is worth considering the current 
paradigm about the role of some of these genes in altered biology as it may facilitate 
hypothesis generation.  
AGER encodes RAGE which mediates interactions of advanced glycosylation end 
products and these are glycosylated proteins which accumulate in vascular tissue 
during aging and at an accelerated rate in several human disorders including 
diabetes (Kankova et al., 2001). RAGE acts as a receptor for amyloid beta peptide 
and contributes to the translocation of amyloid-beta peptide across the cell 
membrane from the extracellular to the intracellular space in cortical neurons (Yan et 
al., 1996). RAGE signalling plays a critical role in regulating the production and/or 
expression of TNF-α, oxidative stress, and endothelial dysfunction which is of 
relevance to damage in the airways. While predominantly from mouse studies (see 
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in vivo section) the accumulating data suggests that RAGE is critical for both normal 
lung development and the response of the lung to damage.  
HTR4 is a member of the family of serotonin receptors, which are G protein coupled 
receptors that stimulate cAMP production in response to serotonin. Therefore HTR4 
can play a role in neurotransmission and interestingly this gene was also associated 
with smoking behaviours. The activity of this receptor is mediated by G proteins that 
stimulate adenylate cyclase and may have a role in lung development (Hodge et al., 
2013). At this time it is likely HTR4 is related to lung function due to the role in 
neurotransmission. 
HHIP is a member of family of hedgehog-interacting proteins. These proteins are 
conserved morphogens playing a critical role in development. More specifically these 
proteins take part in formation of anteroposterior patterns of limbs as well as 
regulation of left-right asymmetry in the embryo (Ingham & McMahon, 2001). 
GSTCD and INTS12 are the two oppositely transcribed genes at 4q24 locus at the 
centre of association signal for lung function (Figure 2). Nothing is known about the 
function of the former gene. On the other hand, INTS12 encodes a protein that was 
initially discovered as the smallest member of the Integrator Complex that is involved 
in small nuclear RNA (snRNA) processing (Baillat et al., 2005). The role of Integrator 
Complex in snRNA processing was demonstrated in human cell lines (Baillat et al., 
2005) but the specific requirement of INTS12 in snRNA processing has only shown 
in Drosophila melanogaster (Ezzeddine et al., 2011) and nothing is currently known 
about the functional requirement of INTS12 in snRNA processing in human cells. 
Interestingly, a recent study by Chen et al. demonstrated that in the fly, evolutionary 
conserved plant homeodomain (PHD) motif protein domain of INTS12 is dispensable 
for snRNA processing while N-terminal domain is both necessary and sufficient for 
this processing to occur (J. Chen, Waltenspiel, Warren, & Wagner, 2013). This 
strongly suggested the existence of important and unrealized functions for this gene. 
Although homozygote INTS12 knockout mouse models are lethal but there is no 
overt phenotype observed for equivalent manipulation of GSTCD (Obeidat et al., 
2013). Crucially, Obeidat et al. reported that multiple SNPs associated with lung 
function at 4q24 are also in eQTL with INTS12 expression but this was not observed 
for other genes in the locus (Obeidat et al., 2013). NPNT is also present within the 
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associated 4q24 locus. This gene plays a role in the kidney development by acting 
as a functional ligand of integrin α-8/β-1. Together with α-8/β-1, NPNT’s protein 
regulates the expression of GDNF which is essential for the kidney development 
(Linton, Martin, & Reichardt, 2007), however there is a clear role for integrins in the 
airways including links to airway fibrosis. It has also been suggested that NPNT 
promotes osteoblast differentiation via the epidermal growth factor-like repeats 
(Kahai, Lee, Seth, & Yang, 2010). 
 
Summary and future perspectives 
As GWAS and particularly GWAS meta-analyses involve increasingly larger 
population sizes and improved integration of the genome (including rare sequence 
variation) continue to identify novel loci for a large number of human traits there is a 
pressing need to develop technologies to translate these findings. This functional 
understanding is critical to move from genetics to translational medicine identifying 
potentially novel targets for therapeutic intervention. This is particularly important in 
diseases such as COPD where the current medicines available provide relief from 
symptoms but do not address the underlying progression of the disease.    
This translation has been significantly facilitated by recent developments in the areas 
outlined in this review (Figure 18) but particularly in functional annotation of the 
genome, mapping chromatin interactions, cell and tissue eQTLs, transgenic mice 
and more recently genome editing approaches. While all of these approaches have a 
role to play, it is clear careful experimental design using the most appropriate (ideally 
human) system that is critical to interpretation and so we envisage a focussing of 
approaches to include primary adult human cells, or excitingly, the potential for 
human iPSCs to contribute to these approaches. As genome editing technologies, 
particularly using CRISPR/Cas9 become routine, efficient and scalable, we envisage 
this methodology to play a pivotal role in the investigation of both gene and single 
variant in biological systems both in vivo and in vitro.  
While we have focussed to genetic association in the context of GWAS it is important 
to note that epigenome-wide association studies (EWAS) with traits and human 
diseases are increasing and there is an opportunity to combine GWAS and EWAS 
findings particularly for scalable epigenetic changes such as DNA methylation. This 
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approach may provide greater insight and initial starting points for functional 
translation. 
Figure 19: An overview of tools that can be used for translation of genetic association findings into 
biological function allowing for ultimate therapeutic intervention.  
 
Competing interests 
Authors declare no competing interests. 
Acknowledgements 
The authors’ laboratory is funded by grants from Medical Research Council 
(G10000861) and Asthma UK (AUK-PG-2013-188). 
 
References 
(GOLD), G. I. f. C. O. L. D. (2015). Global Strategy for the Diagnosis, Management 
and Prevention of COPD. Retrieved from: http://www.goldcopd.org/ 
Adli, M., & Bernstein, B. E. (2011). Whole-genome chromatin profiling from limited 
numbers of cells using nano-ChIP-seq. Nat Protoc, 6(10), 1656-1668. doi: 
10.1038/nprot.2011.402 
Afonso, A. S., Verhamme, K. M., Sturkenboom, M. C., & Brusselle, G. G. (2011). 
COPD in the general population: prevalence, incidence and survival. Respir 
Med, 105(12), 1872-1884. doi: 10.1016/j.rmed.2011.06.012 
73 
 
Bailey, T., Krajewski, P., Ladunga, I., Lefebvre, C., Li, Q., Liu, T., . . . Zhang, J. 
(2013). Practical guidelines for the comprehensive analysis of ChIP-seq data. 
PLoS Comput Biol, 9(11), e1003326. doi: 10.1371/journal.pcbi.1003326 
Baillat, D., Hakimi, M. A., Naar, A. M., Shilatifard, A., Cooch, N., & Shiekhattar, R. 
(2005). Integrator, a multiprotein mediator of small nuclear RNA processing, 
associates with the C-terminal repeat of RNA polymerase II. Cell, 123(2), 265-
276. doi: 10.1016/j.cell.2005.08.019 
Bannister, A. J., & Kouzarides, T. (2011). Regulation of chromatin by histone 
modifications. Cell Res, 21(3), 381-395. doi: 10.1038/cr.2011.22 
Barton, S. J., Koppelman, G. H., Vonk, J. M., Browning, C. A., Nolte, I. M., Stewart, 
C. E., . . . Sayers, I. (2009). PLAUR polymorphisms are associated with 
asthma, PLAUR levels, and lung function decline. J Allergy Clin Immunol, 
123(6), 1391-1400 e1317. doi: 10.1016/j.jaci.2009.03.014 
Bellusci, S., Furuta, Y., Rush, M. G., Henderson, R., Winnier, G., & Hogan, B. L. 
(1997). Involvement of Sonic hedgehog (Shh) in mouse embryonic lung 
growth and morphogenesis. Development, 124(1), 53-63.  
Bentley, R. W., Pearson, J., Gearry, R. B., Barclay, M. L., McKinney, C., Merriman, 
T. R., & Roberts, R. L. (2010). Association of higher DEFB4 genomic copy 
number with Crohn's disease. Am J Gastroenterol, 105(2), 354-359. doi: 
10.1038/ajg.2009.582 
Bertin, G., Poujeol, C., Rubera, I., Poujeol, P., & Tauc, M. (2005). In vivo Cre/loxP 
mediated recombination in mouse Clara cells. Transgenic Res, 14(5), 645-
654. doi: 10.1007/s11248-005-7214-0 
Bierhaus, A., & Nawroth, P. P. (2009). Multiple levels of regulation determine the role 
of the receptor for AGE (RAGE) as common soil in inflammation, immune 
responses and diabetes mellitus and its complications. Diabetologia, 52(11), 
2251-2263. doi: 10.1007/s00125-009-1458-9 
Bocchini, V., Mazzolla, R., Barluzzi, R., Blasi, E., Sick, P., & Kettenmann, H. (1992). 
An immortalized cell line expresses properties of activated microglial cells. J 
Neurosci Res, 31(4), 616-621. doi: 10.1002/jnr.490310405 
Brehm, J. M., Hagiwara, K., Tesfaigzi, Y., Bruse, S., Mariani, T. J., Bhattacharya, S., 
. . . Celedon, J. C. (2011). Identification of FGF7 as a novel susceptibility 
locus for chronic obstructive pulmonary disease. Thorax, 66(12), 1085-1090. 
doi: 10.1136/thoraxjnl-2011-200017 
Brown, S. D., & Moore, M. W. (2012). Towards an encyclopaedia of mammalian 
gene function: the International Mouse Phenotyping Consortium. Dis Model 
Mech, 5(3), 289-292. doi: 10.1242/dmm.009878 
Calarco, J. A., Xing, Y., Caceres, M., Calarco, J. P., Xiao, X., Pan, Q., . . . Blencowe, 
B. J. (2007). Global analysis of alternative splicing differences between 
humans and chimpanzees. Genes Dev, 21(22), 2963-2975. doi: 
10.1101/gad.1606907 
Castaldi, P. J., Cho, M. H., Litonjua, A. A., Bakke, P., Gulsvik, A., Lomas, D. A., . . . 
Eclipse, I. (2011). The association of genome-wide significant spirometric loci 
with chronic obstructive pulmonary disease susceptibility. Am J Respir Cell 
Mol Biol, 45(6), 1147-1153. doi: 10.1165/rcmb.2011-0055OC 
Castaldi, P. J., Cho, M. H., San Jose Estepar, R., McDonald, M. L., Laird, N., Beaty, 
T. H., . . . Investigators, C. O. (2014). Genome-wide association identifies 
regulatory Loci associated with distinct local histogram emphysema patterns. 
Am J Respir Crit Care Med, 190(4), 399-409. doi: 10.1164/rccm.201403-
0569OC 
74 
 
Celedon, J. C., Lange, C., Raby, B. A., Litonjua, A. A., Palmer, L. J., DeMeo, D. L., . 
. . Silverman, E. K. (2004). The transforming growth factor-beta1 (TGFB1) 
gene is associated with chronic obstructive pulmonary disease (COPD). Hum 
Mol Genet, 13(15), 1649-1656. doi: 10.1093/hmg/ddh171 
Chappell, S., Daly, L., Morgan, K., Baranes, T. G., Roca, J., Rabinovich, R., . . . 
Kalsheker, N. (2006). The SERPINE2 gene and chronic obstructive 
pulmonary disease. Am J Hum Genet, 79(1), 184-186; author reply 186-187. 
doi: 10.1086/505268 
Chen, J., Waltenspiel, B., Warren, W. D., & Wagner, E. J. (2013). Functional 
analysis of the integrator subunit 12 identifies a microdomain that mediates 
activation of the Drosophila integrator complex. J Biol Chem, 288(7), 4867-
4877. doi: 10.1074/jbc.M112.425892 
Chen, W., Brehm, J. M., Manichaikul, A., Cho, M. H., Boutaoui, N., Yan, Q., . . . 
Celedon, J. C. (2015). A genome-wide association study of chronic 
obstructive pulmonary disease in Hispanics. Ann Am Thorac Soc, 12(3), 340-
348. doi: 10.1513/AnnalsATS.201408-380OC 
Cheng, D. T., Kim, D. K., Cockayne, D. A., Belousov, A., Bitter, H., Cho, M. H., . . . 
Investigators, E. (2013). Systemic soluble receptor for advanced glycation 
endproducts is a biomarker of emphysema and associated with AGER genetic 
variants in patients with chronic obstructive pulmonary disease. Am J Respir 
Crit Care Med, 188(8), 948-957. doi: 10.1164/rccm.201302-0247OC 
Cho, M. H., Boutaoui, N., Klanderman, B. J., Sylvia, J. S., Ziniti, J. P., Hersh, C. P., . 
. . Silverman, E. K. (2010). Variants in FAM13A are associated with chronic 
obstructive pulmonary disease. Nat Genet, 42(3), 200-202. doi: 
10.1038/ng.535 
Cho, M. H., Castaldi, P. J., Hersh, C. P., Hobbs, B. D., Barr, R. G., Tal-Singer, R., . . 
. Investigators, C. O. (2015). A Genome-wide Association Study of 
Emphysema and Airway Quantitative Imaging Phenotypes. Am J Respir Crit 
Care Med. doi: 10.1164/rccm.201501-0148OC 
Cho, M. H., Castaldi, P. J., Wan, E. S., Siedlinski, M., Hersh, C. P., Demeo, D. L., . . 
. Investigators, C. O. (2012). A genome-wide association study of COPD 
identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet, 21(4), 
947-957. doi: 10.1093/hmg/ddr524 
Cho, M. H., McDonald, M. L., Zhou, X., Mattheisen, M., Castaldi, P. J., Hersh, C. P., 
. . . Investigators, C. O. (2014). Risk loci for chronic obstructive pulmonary 
disease: a genome-wide association study and meta-analysis. Lancet Respir 
Med, 2(3), 214-225. doi: 10.1016/S2213-2600(14)70002-5 
Ciprandi, G., Capasso, M., Tosca, M., Salpietro, C., Salpietro, A., Marseglia, G., & 
La Rosa, M. (2012). A forced expiratory flow at 25-75% value <65% of 
predicted should be considered abnormal: a real-world, cross-sectional study. 
Allergy Asthma Proc, 33(1), e5-8. doi: 10.2500/aap.2012.33.3524 
Claussnitzer, M., Dankel, S. N., Kim, K. H., Quon, G., Meuleman, W., Haugen, C., . . 
. Kellis, M. (2015). FTO Obesity Variant Circuitry and Adipocyte Browning in 
Humans. N Engl J Med, 373(10), 895-907. doi: 10.1056/NEJMoa1502214 
Conrad, D. F., Pinto, D., Redon, R., Feuk, L., Gokcumen, O., Zhang, Y., . . . Hurles, 
M. E. (2010). Origins and functional impact of copy number variation in the 
human genome. Nature, 464(7289), 704-712. doi: 10.1038/nature08516 
Consortium, E. P. (2004). The ENCODE (ENCyclopedia Of DNA Elements) Project. 
Science, 306(5696), 636-640. doi: 10.1126/science.1105136 
75 
 
Consortium, E. P., Birney, E., Stamatoyannopoulos, J. A., Dutta, A., Guigo, R., 
Gingeras, T. R., . . . de Jong, P. J. (2007). Identification and analysis of 
functional elements in 1% of the human genome by the ENCODE pilot 
project. Nature, 447(7146), 799-816. doi: 10.1038/nature05874 
Coultas, D. B., Hanis, C. L., Howard, C. A., Skipper, B. J., & Samet, J. M. (1991). 
Heritability of ventilatory function in smoking and nonsmoking New Mexico 
Hispanics. Am Rev Respir Dis, 144(4), 770-775. doi: 
10.1164/ajrccm/144.4.770 
Dawkins, P. A., & Stockley, R. A. (2001). Animal models of chronic obstructive 
pulmonary disease. Thorax, 56(12), 972-977.  
Deaton, A. M., & Bird, A. (2011). CpG islands and the regulation of transcription. 
Genes Dev, 25(10), 1010-1022. doi: 10.1101/gad.2037511 
Demeo, D. L., Mariani, T. J., Lange, C., Srisuma, S., Litonjua, A. A., Celedon, J. C., . 
. . Silverman, E. K. (2006). The SERPINE2 gene is associated with chronic 
obstructive pulmonary disease. Am J Hum Genet, 78(2), 253-264. doi: 
10.1086/499828 
DeMeo, D. L., & Silverman, E. K. (2003). Genetics of chronic obstructive pulmonary 
disease. Semin Respir Crit Care Med, 24(2), 151-160. doi: 10.1055/s-2003-
39014 
DeMeo, D. L., & Silverman, E. K. (2004). Alpha1-antitrypsin deficiency. 2: genetic 
aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers 
of emphysema risk. Thorax, 59(3), 259-264.  
Diez-Villanueva, A., Mallona, I., & Peinado, M. A. (2015). Wanderer, an interactive 
viewer to explore DNA methylation and gene expression data in human 
cancer. Epigenetics Chromatin, 8, 22. doi: 10.1186/s13072-015-0014-8 
Dijkstra, A. E., Boezen, H. M., van den Berge, M., Vonk, J. M., Hiemstra, P. S., Barr, 
R. G., . . . LifeLines Cohort Study, g. (2015). Dissecting the genetics of 
chronic mucus hypersecretion in smokers with and without COPD. Eur Respir 
J, 45(1), 60-75. doi: 10.1183/09031936.00093314 
Dijkstra, A. E., Postma, D. S., van Ginneken, B., Wielputz, M. O., Schmidt, M., 
Becker, N., . . . Groen, H. J. (2015). Novel genes for airway wall thickness 
identified with combined genome-wide association and expression analyses. 
Am J Respir Crit Care Med, 191(5), 547-556. doi: 10.1164/rccm.201405-
0840OC 
Edwards, J., Belvisi, M., Dahlen, S. E., Holgate, S., & Holmes, A. (2015). Human 
tissue models for a human disease: what are the barriers? Thorax, 70(7), 695-
697. doi: 10.1136/thoraxjnl-2014-206648 
Eriksson, S. (1965). Studies in alpha 1-antitrypsin deficiency. Acta Med Scand 
Suppl, 432, 1-85.  
Ezzeddine, N., Chen, J., Waltenspiel, B., Burch, B., Albrecht, T., Zhuo, M., . . . 
Wagner, E. J. (2011). A subset of Drosophila integrator proteins is essential 
for efficient U7 snRNA and spliceosomal snRNA 3'-end formation. Mol Cell 
Biol, 31(2), 328-341. doi: 10.1128/MCB.00943-10 
Favorov, A., Mularoni, L., Cope, L. M., Medvedeva, Y., Mironov, A. A., Makeev, V. J., 
& Wheelan, S. J. (2012). Exploring massive, genome scale datasets with the 
GenometriCorr package. PLoS Comput Biol, 8(5), e1002529. doi: 
10.1371/journal.pcbi.1002529 
Fellermann, K., Stange, D. E., Schaeffeler, E., Schmalzl, H., Wehkamp, J., Bevins, 
C. L., . . . Stange, E. F. (2006). A chromosome 8 gene-cluster polymorphism 
76 
 
with low human beta-defensin 2 gene copy number predisposes to Crohn 
disease of the colon. Am J Hum Genet, 79(3), 439-448. doi: 10.1086/505915 
Ferhani, N., Letuve, S., Kozhich, A., Thibaudeau, O., Grandsaigne, M., Maret, M., . . 
. Pretolani, M. (2010). Expression of high-mobility group box 1 and of receptor 
for advanced glycation end products in chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med, 181(9), 917-927. doi: 
10.1164/rccm.200903-0340OC 
Fode, P., Jespersgaard, C., Hardwick, R. J., Bogle, H., Theisen, M., Dodoo, D., . . . 
Hollox, E. J. (2011). Determination of beta-defensin genomic copy number in 
different populations: a comparison of three methods. PLoS One, 6(2), 
e16768. doi: 10.1371/journal.pone.0016768 
Gaens, K. H., Ferreira, I., van der Kallen, C. J., van Greevenbroek, M. M., Blaak, E. 
E., Feskens, E. J., . . . Schalkwijk, C. G. (2009). Association of polymorphism 
in the receptor for advanced glycation end products (RAGE) gene with 
circulating RAGE levels. J Clin Endocrinol Metab, 94(12), 5174-5180. doi: 
10.1210/jc.2009-1067 
Gaj, T., Gersbach, C. A., & Barbas, C. F., 3rd. (2013). ZFN, TALEN, and 
CRISPR/Cas-based methods for genome engineering. Trends Biotechnol, 
31(7), 397-405. doi: 10.1016/j.tibtech.2013.04.004 
Genomes Project, C., Abecasis, G. R., Auton, A., Brooks, L. D., DePristo, M. A., 
Durbin, R. M., . . . McVean, G. A. (2012). An integrated map of genetic 
variation from 1,092 human genomes. Nature, 491(7422), 56-65. doi: 
10.1038/nature11632 
Gibney, E. R., & Nolan, C. M. (2010). Epigenetics and gene expression. Heredity 
(Edinb), 105(1), 4-13. doi: 10.1038/hdy.2010.54 
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., . . . Qi, L. 
S. (2013). CRISPR-mediated modular RNA-guided regulation of transcription 
in eukaryotes. Cell, 154(2), 442-451. doi: 10.1016/j.cell.2013.06.044 
Gunther, E. J., Belka, G. K., Wertheim, G. B., Wang, J., Hartman, J. L., Boxer, R. B., 
& Chodosh, L. A. (2002). A novel doxycycline-inducible system for the 
transgenic analysis of mammary gland biology. FASEB J, 16(3), 283-292. doi: 
10.1096/fj.01-0551com 
Hackett, T. L., Holloway, R., Holgate, S. T., & Warner, J. A. (2008). Dynamics of pro-
inflammatory and anti-inflammatory cytokine release during acute 
inflammation in chronic obstructive pulmonary disease: an ex vivo study. 
Respir Res, 9, 47. doi: 10.1186/1465-9921-9-47 
Hallberg, J., Dominicus, A., Eriksson, U. K., Gerhardsson de Verdier, M., Pedersen, 
N. L., Dahlback, M., . . . Svartengren, M. (2008). Interaction between smoking 
and genetic factors in the development of chronic bronchitis. Am J Respir Crit 
Care Med, 177(5), 486-490. doi: 10.1164/rccm.200704-565OC 
Hancock, D. B., Artigas, M. S., Gharib, S. A., Henry, A., Manichaikul, A., Ramasamy, 
A., . . . London, S. J. (2012). Genome-wide joint meta-analysis of SNP and 
SNP-by-smoking interaction identifies novel loci for pulmonary function. PLoS 
Genet, 8(12), e1003098. doi: 10.1371/journal.pgen.1003098 
Hancock, D. B., Eijgelsheim, M., Wilk, J. B., Gharib, S. A., Loehr, L. R., Marciante, K. 
D., . . . London, S. J. (2010). Meta-analyses of genome-wide association 
studies identify multiple loci associated with pulmonary function. Nat Genet, 
42(1), 45-52. doi: 10.1038/ng.500 
77 
 
Hankinson, J. L., Odencrantz, J. R., & Fedan, K. B. (1999). Spirometric reference 
values from a sample of the general U.S. population. Am J Respir Crit Care 
Med, 159(1), 179-187. doi: 10.1164/ajrccm.159.1.9712108 
Hansel, N. N., Ruczinski, I., Rafaels, N., Sin, D. D., Daley, D., Malinina, A., . . . 
Barnes, K. C. (2013). Genome-wide study identifies two loci associated with 
lung function decline in mild to moderate COPD. Hum Genet, 132(1), 79-90. 
doi: 10.1007/s00439-012-1219-6 
Hansen, J. E., Sun, X. G., & Wasserman, K. (2007). Spirometric criteria for airway 
obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not 
< 70%. Chest, 131(2), 349-355. doi: 10.1378/chest.06-1349 
Hao, K., Bosse, Y., Nickle, D. C., Pare, P. D., Postma, D. S., Laviolette, M., . . . Sin, 
D. D. (2012). Lung eQTLs to help reveal the molecular underpinnings of 
asthma. PLoS Genet, 8(11), e1003029. doi: 10.1371/journal.pgen.1003029 
Hardin M, S. E. (2014). Chronic obstructive pulmonary disease genetics: a review of 
the past and a look into the future. J COPD F, 1(1), 33-46  
Hardwick, R. J., Machado, L. R., Zuccherato, L. W., Antolinos, S., Xue, Y., Shawa, 
N., . . . Hollox, E. J. (2011). A worldwide analysis of beta-defensin copy 
number variation suggests recent selection of a high-expressing DEFB103 
gene copy in East Asia. Hum Mutat, 32(7), 743-750. doi: 
10.1002/humu.21491 
Heger, A., Webber, C., Goodson, M., Ponting, C. P., & Lunter, G. (2013). GAT: a 
simulation framework for testing the association of genomic intervals. 
Bioinformatics, 29(16), 2046-2048. doi: 10.1093/bioinformatics/btt343 
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., . . . Glass, C. K. 
(2010). Simple combinations of lineage-determining transcription factors 
prime cis-regulatory elements required for macrophage and B cell identities. 
Mol Cell, 38(4), 576-589. doi: 10.1016/j.molcel.2010.05.004 
Hellman, L. M., & Fried, M. G. (2007). Electrophoretic mobility shift assay (EMSA) for 
detecting protein-nucleic acid interactions. Nat Protoc, 2(8), 1849-1861. doi: 
10.1038/nprot.2007.249 
Hemani, G., Shakhbazov, K., Westra, H. J., Esko, T., Henders, A. K., McRae, A. F., . 
. . Powell, J. E. (2014). Detection and replication of epistasis influencing 
transcription in humans. Nature, 508(7495), 249-253. doi: 
10.1038/nature13005 
Hemminki, K., Li, X., Sundquist, K., & Sundquist, J. (2008a). Familial risks for chronic 
obstructive pulmonary disease among siblings based on hospitalisations in 
Sweden. J Epidemiol Community Health, 62(5), 398-401. doi: 
10.1136/jech.2007.063156 
Hemminki, K., Li, X., Sundquist, K., & Sundquist, J. (2008b). Familial risks for 
common diseases: etiologic clues and guidance to gene identification. Mutat 
Res, 658(3), 247-258. doi: 10.1016/j.mrrev.2008.01.002 
Hirschhorn, J. N., & Daly, M. J. (2005). Genome-wide association studies for 
common diseases and complex traits. Nat Rev Genet, 6(2), 95-108. doi: 
10.1038/nrg1521 
Hodge, E., Nelson, C. P., Miller, S., Billington, C. K., Stewart, C. E., Swan, C., . . . 
Sayers, I. (2013). HTR4 gene structure and altered expression in the 
developing lung. Respir Res, 14, 77. doi: 10.1186/1465-9921-14-77 
Hofmann, M. A., Drury, S., Hudson, B. I., Gleason, M. R., Qu, W., Lu, Y., . . . 
Schmidt, A. M. (2002). RAGE and arthritis: the G82S polymorphism amplifies 
78 
 
the inflammatory response. Genes Immun, 3(3), 123-135. doi: 
10.1038/sj.gene.6363861 
Hollox, E. J., Huffmeier, U., Zeeuwen, P. L., Palla, R., Lascorz, J., Rodijk-Olthuis, D., 
. . . Schalkwijk, J. (2008). Psoriasis is associated with increased beta-defensin 
genomic copy number. Nat Genet, 40(1), 23-25. doi: 10.1038/ng.2007.48 
Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J. X., . . . et al. (1995). The 
receptor for advanced glycation end products (RAGE) is a cellular binding site 
for amphoterin. Mediation of neurite outgrowth and co-expression of rage and 
amphoterin in the developing nervous system. J Biol Chem, 270(43), 25752-
25761.  
House, J. S., Li, H., DeGraff, L. M., Flake, G., Zeldin, D. C., & London, S. J. (2015). 
Genetic variation in HTR4 and lung function: GWAS follow-up in mouse. 
FASEB J, 29(1), 323-335. doi: 10.1096/fj.14-253898 
Huang da, W., Sherman, B. T., & Lempicki, R. A. (2009). Bioinformatics enrichment 
tools: paths toward the comprehensive functional analysis of large gene lists. 
Nucleic Acids Res, 37(1), 1-13. doi: 10.1093/nar/gkn923 
Hubert, H. B., Fabsitz, R. R., Feinleib, M., & Gwinn, C. (1982). Genetic and 
environmental influences on pulmonary function in adult twins. Am Rev Respir 
Dis, 125(4), 409-415.  
Hughes, J. R., Roberts, N., McGowan, S., Hay, D., Giannoulatou, E., Lynch, M., . . . 
Higgs, D. R. (2014). Analysis of hundreds of cis-regulatory landscapes at high 
resolution in a single, high-throughput experiment. Nat Genet, 46(2), 205-212. 
doi: 10.1038/ng.2871 
Hukkinen, M., Kaprio, J., Broms, U., Viljanen, A., Kotz, D., Rantanen, T., & 
Korhonen, T. (2011). Heritability of lung function: a twin study among never-
smoking elderly women. Twin Res Hum Genet, 14(5), 401-407. doi: 
10.1375/twin.14.5.401 
Hunninghake, G. M., Cho, M. H., Tesfaigzi, Y., Soto-Quiros, M. E., Avila, L., Lasky-
Su, J., . . . Celedon, J. C. (2009). MMP12, lung function, and COPD in high-
risk populations. N Engl J Med, 361(27), 2599-2608. doi: 
10.1056/NEJMoa0904006 
Hurd, S., & Pauwels, R. (2002). Global Initiative for Chronic Obstructive Lung 
Diseases (GOLD). Pulm Pharmacol Ther, 15(4), 353-355.  
Ingham, P. W., & McMahon, A. P. (2001). Hedgehog signaling in animal 
development: paradigms and principles. Genes Dev, 15(23), 3059-3087. doi: 
10.1101/gad.938601 
International HapMap, C. (2005). A haplotype map of the human genome. Nature, 
437(7063), 1299-1320. doi: 10.1038/nature04226 
Irving, J. A., Pike, R. N., Lesk, A. M., & Whisstock, J. C. (2000). Phylogeny of the 
serpin superfamily: implications of patterns of amino acid conservation for 
structure and function. Genome Res, 10(12), 1845-1864.  
Ivancso, I., Toldi, G., Bohacs, A., Eszes, N., Muller, V., Rigo, J., Jr., . . . Tamasi, L. 
(2013). Relationship of circulating soluble urokinase plasminogen activator 
receptor (suPAR) levels to disease control in asthma and asthmatic 
pregnancy. PLoS One, 8(4), e60697. doi: 10.1371/journal.pone.0060697 
Janciauskiene, S. M., Bals, R., Koczulla, R., Vogelmeier, C., Kohnlein, T., & Welte, 
T. (2011). The discovery of alpha1-antitrypsin and its role in health and 
disease. Respir Med, 105(8), 1129-1139. doi: 10.1016/j.rmed.2011.02.002 
Jin, Z., Chung, J. W., Mei, W., Strack, S., He, C., Lau, G. W., & Yang, J. (2015). 
Regulation of nuclear-cytoplasmic shuttling and function of Family with 
79 
 
sequence similarity 13, member A (Fam13a), by B56-containing PP2As and 
Akt. Mol Biol Cell, 26(6), 1160-1173. doi: 10.1091/mbc.E14-08-1276 
Joung, J. K., & Sander, J. D. (2013). TALENs: a widely applicable technology for 
targeted genome editing. Nat Rev Mol Cell Biol, 14(1), 49-55. doi: 
10.1038/nrm3486 
Kahai, S., Lee, S. C., Seth, A., & Yang, B. B. (2010). Nephronectin promotes 
osteoblast differentiation via the epidermal growth factor-like repeats. FEBS 
Lett, 584(1), 233-238. doi: 10.1016/j.febslet.2009.11.077 
Kankova, K., Zahejsky, J., Marova, I., Muzik, J., Kuhrova, V., Blazkova, M., . . . 
Vacha, J. (2001). Polymorphisms in the RAGE gene influence susceptibility to 
diabetes-associated microvascular dermatoses in NIDDM. J Diabetes 
Complications, 15(4), 185-192.  
Kiefer, J. C. (2007). Epigenetics in development. Dev Dyn, 236(4), 1144-1156. doi: 
10.1002/dvdy.21094 
Kim, W. J., Lim, M. N., Hong, Y., Silverman, E. K., Lee, J. H., Jung, B. H., . . . Lee, S. 
D. (2014). Association of lung function genes with chronic obstructive 
pulmonary disease. Lung, 192(4), 473-480. doi: 10.1007/s00408-014-9579-4 
Klimentidis, Y. C., Vazquez, A. I., de Los Campos, G., Allison, D. B., Dransfield, M. 
T., & Thannickal, V. J. (2013). Heritability of pulmonary function estimated 
from pedigree and whole-genome markers. Front Genet, 4, 174. doi: 
10.3389/fgene.2013.00174 
Konermann, S., Brigham, M. D., Trevino, A. E., Hsu, P. D., Heidenreich, M., Cong, 
L., . . . Zhang, F. (2013). Optical control of mammalian endogenous 
transcription and epigenetic states. Nature, 500(7463), 472-476. doi: 
10.1038/nature12466 
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., 
Barcena, C., . . . Zhang, F. (2015). Genome-scale transcriptional activation by 
an engineered CRISPR-Cas9 complex. Nature, 517(7536), 583-588. doi: 
10.1038/nature14136 
Kong, X., Cho, M. H., Anderson, W., Coxson, H. O., Muller, N., Washko, G., . . . 
Investigators, E. S. N. (2011). Genome-wide association study identifies 
BICD1 as a susceptibility gene for emphysema. Am J Respir Crit Care Med, 
183(1), 43-49. doi: 10.1164/rccm.201004-0541OC 
Kwan, T., Benovoy, D., Dias, C., Gurd, S., Provencher, C., Beaulieu, P., . . . 
Majewski, J. (2008). Genome-wide analysis of transcript isoform variation in 
humans. Nat Genet, 40(2), 225-231. doi: 10.1038/ng.2007.57 
Lander, E. S., & Schork, N. J. (1994). Genetic dissection of complex traits. Science, 
265(5181), 2037-2048.  
Landt, S. G., Marinov, G. K., Kundaje, A., Kheradpour, P., Pauli, F., Batzoglou, S., . . 
. Snyder, M. (2012). ChIP-seq guidelines and practices of the ENCODE and 
modENCODE consortia. Genome Res, 22(9), 1813-1831. doi: 
10.1101/gr.136184.111 
Latchman, D. S. (1997). Transcription factors: an overview. Int J Biochem Cell Biol, 
29(12), 1305-1312.  
Laurell, C. B., & Eriksson, S. (2013). The electrophoretic alpha1-globulin pattern of 
serum in alpha1-antitrypsin deficiency. 1963. COPD, 10 Suppl 1, 3-8. doi: 
10.3109/15412555.2013.771956 
Lebecque, P., Kiakulanda, P., & Coates, A. L. (1993). Spirometry in the asthmatic 
child: is FEF25-75 a more sensitive test than FEV1/FVC? Pediatr Pulmonol, 
16(1), 19-22.  
80 
 
Lee, B. Y., Cho, S., Shin, D. H., & Kim, H. (2011). Genome-wide association study of 
copy number variations associated with pulmonary function measures in 
Korea Associated Resource (KARE) cohorts. Genomics, 97(2), 101-105. doi: 
10.1016/j.ygeno.2010.11.001 
Lee, J. H., Cho, M. H., Hersh, C. P., McDonald, M. L., Crapo, J. D., Bakke, P. S., . . . 
Investigators, E. (2014). Genetic susceptibility for chronic bronchitis in chronic 
obstructive pulmonary disease. Respir Res, 15, 113. doi: 10.1186/s12931-
014-0113-2 
Lee, S., Abecasis, G. R., Boehnke, M., & Lin, X. (2014). Rare-variant association 
analysis: study designs and statistical tests. Am J Hum Genet, 95(1), 5-23. 
doi: 10.1016/j.ajhg.2014.06.009 
Lee, T. I., & Young, R. A. (2000). Transcription of eukaryotic protein-coding genes. 
Annu Rev Genet, 34, 77-137. doi: 10.1146/annurev.genet.34.1.77 
Lewitter, F. I., Tager, I. B., McGue, M., Tishler, P. V., & Speizer, F. E. (1984). 
Genetic and environmental determinants of level of pulmonary function. Am J 
Epidemiol, 120(4), 518-530.  
Li, H., Cho, S. N., Evans, C. M., Dickey, B. F., Jeong, J. W., & DeMayo, F. J. (2008). 
Cre-mediated recombination in mouse Clara cells. Genesis, 46(6), 300-307. 
doi: 10.1002/dvg.20396 
Li, X., Hastie, A. T., Hawkins, G. A., Moore, W. C., Ampleford, E. J., Milosevic, J., . . . 
Bleecker, E. R. (2015). eQTL of bronchial epithelial cells and bronchial 
alveolar lavage deciphers GWAS-identified asthma genes. Allergy. doi: 
10.1111/all.12683 
Li, Y., & Tollefsbol, T. O. (2011). DNA methylation detection: bisulfite genomic 
sequencing analysis. Methods Mol Biol, 791, 11-21. doi: 10.1007/978-1-
61779-316-5_2 
Lieberman, J. (1969). Heterozygous and homozygous alpha-antitrypsin deficiency in 
patients with pulmonary emphysema. N Engl J Med, 281(6), 279-284. doi: 
10.1056/NEJM196908072810601 
Linton, J. M., Martin, G. R., & Reichardt, L. F. (2007). The ECM protein nephronectin 
promotes kidney development via integrin alpha8beta1-mediated stimulation 
of Gdnf expression. Development, 134(13), 2501-2509. doi: 
10.1242/dev.005033 
Loth, D. W., Artigas, M. S., Gharib, S. A., Wain, L. V., Franceschini, N., Koch, B., . . . 
London, S. J. (2014). Genome-wide association analysis identifies six new 
loci associated with forced vital capacity. Nat Genet, 46(7), 669-677. doi: 
10.1038/ng.3011 
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., . . . 
Memish, Z. A. (2012). Global and regional mortality from 235 causes of death 
for 20 age groups in 1990 and 2010: a systematic analysis for the Global 
Burden of Disease Study 2010. Lancet, 380(9859), 2095-2128. doi: 
10.1016/S0140-6736(12)61728-0 
Luo, W., Obeidat, M., Di Narzo, A. F., Chen, R., Sin, D. D., Pare, P. D., & Hao, K. 
(2015). Airway Epithelial Expression Quantitative Trait Loci Reveal Genes 
Underlying Asthma and Other Airway Diseases. Am J Respir Cell Mol Biol. 
doi: 10.1165/rcmb.2014-0381OC 
Maeder, M. L., Linder, S. J., Cascio, V. M., Fu, Y., Ho, Q. H., & Joung, J. K. (2013). 
CRISPR RNA-guided activation of endogenous human genes. Nat Methods, 
10(10), 977-979. doi: 10.1038/nmeth.2598 
Maher, B. (2012). ENCODE: The human encyclopaedia. Nature, 489(7414), 46-48.  
81 
 
Majewski, J., & Pastinen, T. (2011). The study of eQTL variations by RNA-seq: from 
SNPs to phenotypes. Trends Genet, 27(2), 72-79. doi: 
10.1016/j.tig.2010.10.006 
Mali, P., Aach, J., Stranges, P. B., Esvelt, K. M., Moosburner, M., Kosuri, S., . . . 
Church, G. M. (2013). CAS9 transcriptional activators for target specificity 
screening and paired nickases for cooperative genome engineering. Nat 
Biotechnol, 31(9), 833-838. doi: 10.1038/nbt.2675 
Manichaikul, A., Hoffman, E. A., Smolonska, J., Gao, W., Cho, M. H., Baumhauer, 
H., . . . Barr, R. G. (2014). Genome-wide study of percent emphysema on 
computed tomography in the general population. The Multi-Ethnic Study of 
Atherosclerosis Lung/SNP Health Association Resource Study. Am J Respir 
Crit Care Med, 189(4), 408-418. doi: 10.1164/rccm.201306-1061OC 
Marchini, J., & Howie, B. (2010). Genotype imputation for genome-wide association 
studies. Nat Rev Genet, 11(7), 499-511. doi: 10.1038/nrg2796 
Mardis, E. R. (2011). A decade's perspective on DNA sequencing technology. 
Nature, 470(7333), 198-203. doi: 10.1038/nature09796 
Masters, J. R. (2000). Human cancer cell lines: fact and fantasy. Nat Rev Mol Cell 
Biol, 1(3), 233-236. doi: 10.1038/35043102 
Mathers, C., Boerma, T. and Ma Fat, D. (2008). The global burden of disease: 2004 
update: World Health Organisation. 
Maurano, M. T., Humbert, R., Rynes, E., Thurman, R. E., Haugen, E., Wang, H., . . . 
Stamatoyannopoulos, J. A. (2012). Systematic localization of common 
disease-associated variation in regulatory DNA. Science, 337(6099), 1190-
1195. doi: 10.1126/science.1222794 
McClearn, G. E., Svartengren, M., Pedersen, N. L., Heller, D. A., & Plomin, R. 
(1994). Genetic and environmental influences on pulmonary function in aging 
Swedish twins. J Gerontol, 49(6), 264-268.  
McCloskey, S. C., Patel, B. D., Hinchliffe, S. J., Reid, E. D., Wareham, N. J., & 
Lomas, D. A. (2001). Siblings of patients with severe chronic obstructive 
pulmonary disease have a significant risk of airflow obstruction. Am J Respir 
Crit Care Med, 164(8 Pt 1), 1419-1424. doi: 10.1164/ajrccm.164.8.2105002 
Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., . . . Rebar, E. J. 
(2011). A TALE nuclease architecture for efficient genome editing. Nat 
Biotechnol, 29(2), 143-148. doi: 10.1038/nbt.1755 
Miller, L. A., Wert, S. E., Clark, J. C., Xu, Y., Perl, A. K., & Whitsett, J. A. (2004). 
Role of Sonic hedgehog in patterning of tracheal-bronchial cartilage and the 
peripheral lung. Dev Dyn, 231(1), 57-71. doi: 10.1002/dvdy.20105 
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., . . . 
Force, A. E. T. (2005). Standardisation of spirometry. Eur Respir J, 26(2), 
319-338. doi: 10.1183/09031936.05.00034805 
Nicolae, D. L., Gamazon, E., Zhang, W., Duan, S., Dolan, M. E., & Cox, N. J. (2010). 
Trait-associated SNPs are more likely to be eQTLs: annotation to enhance 
discovery from GWAS. PLoS Genet, 6(4), e1000888. doi: 
10.1371/journal.pgen.1000888 
Niden, A. H. (1967). Bronchiolar and large alveolar cell in pulmonary phospholipid 
metabolism. Science, 158(3806), 1323-1324.  
Obeidat, M., Hao, K., Bosse, Y., Nickle, D. C., Nie, Y., Postma, D. S., . . . Pare, P. D. 
(2015). Molecular mechanisms underlying variations in lung function: a 
systems genetics analysis. Lancet Respir Med. doi: 10.1016/S2213-
2600(15)00380-X 
82 
 
Obeidat, M., Miller, S., Probert, K., Billington, C. K., Henry, A. P., Hodge, E., . . . Hall, 
I. P. (2013). GSTCD and INTS12 regulation and expression in the human 
lung. PLoS One, 8(9), e74630. doi: 10.1371/journal.pone.0074630 
Obeidat, M., Wain, L. V., Shrine, N., Kalsheker, N., Soler Artigas, M., Repapi, E., . . . 
SpiroMeta, C. (2011). A comprehensive evaluation of potential lung function 
associated genes in the SpiroMeta general population sample. PLoS One, 
6(5), e19382. doi: 10.1371/journal.pone.0019382 
Ober, C., Abney, M., & McPeek, M. S. (2001). The genetic dissection of complex 
traits in a founder population. Am J Hum Genet, 69(5), 1068-1079. doi: 
10.1086/324025 
Ohno, S. (1972). So much "junk" DNA in our genome. Brookhaven Symp Biol, 23, 
366-370.  
Palmer, L. J., Celedon, J. C., Chapman, H. A., Speizer, F. E., Weiss, S. T., & 
Silverman, E. K. (2003). Genome-wide linkage analysis of bronchodilator 
responsiveness and post-bronchodilator spirometric phenotypes in chronic 
obstructive pulmonary disease. Hum Mol Genet, 12(10), 1199-1210.  
Pearson, T. A., & Manolio, T. A. (2008). How to interpret a genome-wide association 
study. JAMA, 299(11), 1335-1344. doi: 10.1001/jama.299.11.1335 
Pellegrino, R., Viegi, G., Brusasco, V., Crapo, R. O., Burgos, F., Casaburi, R., . . . 
Wanger, J. (2005). Interpretative strategies for lung function tests. Eur Respir 
J, 26(5), 948-968. doi: 10.1183/09031936.05.00035205 
Pepicelli, C. V., Lewis, P. M., & McMahon, A. P. (1998). Sonic hedgehog regulates 
branching morphogenesis in the mammalian lung. Curr Biol, 8(19), 1083-
1086.  
Perl, A. K., Wert, S. E., Loudy, D. E., Shan, Z., Blair, P. A., & Whitsett, J. A. (2005). 
Conditional recombination reveals distinct subsets of epithelial cells in 
trachea, bronchi, and alveoli. Am J Respir Cell Mol Biol, 33(5), 455-462. doi: 
10.1165/rcmb.2005-0180OC 
Pillai, S. G., Ge, D., Zhu, G., Kong, X., Shianna, K. V., Need, A. C., . . . Investigators, 
I. (2009). A genome-wide association study in chronic obstructive pulmonary 
disease (COPD): identification of two major susceptibility loci. PLoS Genet, 
5(3), e1000421. doi: 10.1371/journal.pgen.1000421 
Pillai, S. G., Kong, X., Edwards, L. D., Cho, M. H., Anderson, W. H., Coxson, H. O., . 
. . Investigators, I. (2010). Loci identified by genome-wide association studies 
influence different disease-related phenotypes in chronic obstructive 
pulmonary disease. Am J Respir Crit Care Med, 182(12), 1498-1505. doi: 
10.1164/rccm.201002-0151OC 
Portelli, M. A., Siedlinski, M., Stewart, C. E., Postma, D. S., Nieuwenhuis, M. A., 
Vonk, J. M., . . . Sayers, I. (2014). Genome-wide protein QTL mapping 
identifies human plasma kallikrein as a post-translational regulator of serum 
uPAR levels. FASEB J, 28(2), 923-934. doi: 10.1096/fj.13-240879 
Ptashne, M., & Gann, A. (1997). Transcriptional activation by recruitment. Nature, 
386(6625), 569-577. doi: 10.1038/386569a0 
Qu, H., & Fang, X. (2013). A brief review on the Human Encyclopedia of DNA 
Elements (ENCODE) project. Genomics Proteomics Bioinformatics, 11(3), 
135-141. doi: 10.1016/j.gpb.2013.05.001 
Quinlan, A. R., & Hall, I. M. (2010). BEDTools: a flexible suite of utilities for 
comparing genomic features. Bioinformatics, 26(6), 841-842. doi: 
10.1093/bioinformatics/btq033 
83 
 
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., . . . 
Global Initiative for Chronic Obstructive Lung, D. (2007). Global strategy for 
the diagnosis, management, and prevention of chronic obstructive pulmonary 
disease: GOLD executive summary. Am J Respir Crit Care Med, 176(6), 532-
555. doi: 10.1164/rccm.200703-456SO 
Rands, C. M., Meader, S., Ponting, C. P., & Lunter, G. (2014). 8.2% of the Human 
genome is constrained: variation in rates of turnover across functional 
element classes in the human lineage. PLoS Genet, 10(7), e1004525. doi: 
10.1371/journal.pgen.1004525 
Redline, S., Tishler, P. V., Lewitter, F. I., Tager, I. B., Munoz, A., & Speizer, F. E. 
(1987). Assessment of genetic and nongenetic influences on pulmonary 
function. A twin study. Am Rev Respir Dis, 135(1), 217-222.  
Repapi, E., Sayers, I., Wain, L. V., Burton, P. R., Johnson, T., Obeidat, M., . . . 
Tobin, M. D. (2010). Genome-wide association study identifies five loci 
associated with lung function. Nat Genet, 42(1), 36-44. doi: 10.1038/ng.501 
Rockman, M. V., & Kruglyak, L. (2006). Genetics of global gene expression. Nat Rev 
Genet, 7(11), 862-872. doi: 10.1038/nrg1964 
Sambamurthy, N., Leme, A. S., Oury, T. D., & Shapiro, S. D. (2015). The receptor for 
advanced glycation end products (RAGE) contributes to the progression of 
emphysema in mice. PLoS One, 10(3), e0118979. doi: 
10.1371/journal.pone.0118979 
Sander, J. D., & Joung, J. K. (2014). CRISPR-Cas systems for editing, regulating 
and targeting genomes. Nat Biotechnol, 32(4), 347-355. doi: 
10.1038/nbt.2842 
Schaub, M. A., Boyle, A. P., Kundaje, A., Batzoglou, S., & Snyder, M. (2012). Linking 
disease associations with regulatory information in the human genome. 
Genome Res, 22(9), 1748-1759. doi: 10.1101/gr.136127.111 
Shlyueva, D., Stampfel, G., & Stark, A. (2014). Transcriptional enhancers: from 
properties to genome-wide predictions. Nat Rev Genet, 15(4), 272-286. doi: 
10.1038/nrg3682 
Shockett, P., Difilippantonio, M., Hellman, N., & Schatz, D. G. (1995). A modified 
tetracycline-regulated system provides autoregulatory, inducible gene 
expression in cultured cells and transgenic mice. Proc Natl Acad Sci U S A, 
92(14), 6522-6526.  
Silverman, E. K., Chapman, H. A., Drazen, J. M., Weiss, S. T., Rosner, B., 
Campbell, E. J., . . . Speizer, F. E. (1998). Genetic epidemiology of severe, 
early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow 
obstruction and chronic bronchitis. Am J Respir Crit Care Med, 157(6 Pt 1), 
1770-1778. doi: 10.1164/ajrccm.157.6.9706014 
Silverman, E. K., Mosley, J. D., Palmer, L. J., Barth, M., Senter, J. M., Brown, A., . . . 
Weiss, S. T. (2002). Genome-wide linkage analysis of severe, early-onset 
chronic obstructive pulmonary disease: airflow obstruction and chronic 
bronchitis phenotypes. Hum Mol Genet, 11(6), 623-632.  
Silverman, E. K., Palmer, L. J., Mosley, J. D., Barth, M., Senter, J. M., Brown, A., . . . 
Weiss, S. T. (2002). Genomewide linkage analysis of quantitative spirometric 
phenotypes in severe early-onset chronic obstructive pulmonary disease. Am 
J Hum Genet, 70(5), 1229-1239. doi: 10.1086/340316 
Simon, M. R., Chinchilli, V. M., Phillips, B. R., Sorkness, C. A., Lemanske, R. F., Jr., 
Szefler, S. J., . . . Blood, I. (2010). Forced expiratory flow between 25% and 
75% of vital capacity and FEV1/forced vital capacity ratio in relation to clinical 
84 
 
and physiological parameters in asthmatic children with normal FEV1 values. 
J Allergy Clin Immunol, 126(3), 527-534 e521-528. doi: 
10.1016/j.jaci.2010.05.016 
Sisson, T. H., Hansen, J. M., Shah, M., Hanson, K. E., Du, M., Ling, T., . . . 
Christensen, P. J. (2006). Expression of the reverse tetracycline-
transactivator gene causes emphysema-like changes in mice. Am J Respir 
Cell Mol Biol, 34(5), 552-560. doi: 10.1165/rcmb.2005-0378OC 
Smith, H. W., & Marshall, C. J. (2010). Regulation of cell signalling by uPAR. Nat 
Rev Mol Cell Biol, 11(1), 23-36. doi: 10.1038/nrm2821 
Soler Artigas, M., Loth, D. W., Wain, L. V., Gharib, S. A., Obeidat, M., Tang, W., . . . 
Tobin, M. D. (2011). Genome-wide association and large-scale follow up 
identifies 16 new loci influencing lung function. Nat Genet, 43(11), 1082-1090. 
doi: 10.1038/ng.941 
Soler Artigas, M., Wain, L. V., Repapi, E., Obeidat, M., Sayers, I., Burton, P. R., . . . 
SpiroMeta, C. (2011). Effect of five genetic variants associated with lung 
function on the risk of chronic obstructive lung disease, and their joint effects 
on lung function. Am J Respir Crit Care Med, 184(7), 786-795. doi: 
10.1164/rccm.201102-0192OC 
Soler Artigas M, W. L., Miller S, Kheirallah AK, Huffman J, Ntalla I, Shrine N, Obeidat 
M, Trochet H, McArdle W, Couto Alves A, Hui J, Zhao JH, Joshi P, Teumer A, 
Albrecht E, Imboden M, Rawal R, Lopez L, Marten J, Enroth S, Surakka I, 
Polasek O, Lyytikäinen LP, Granell R, Hysi P, Flexeder C, Mahajan A, Beilby 
J, Bossé Y, Brandsma CA, Campbell H, Gieger C, Gläser S, Gonzalez J, 
Grallert H, Hammond C, Harris S, Hartikainen AL, Hayward C, Heliövaara M, 
Henderson J, Hocking L, Horikoshi M, Hutri-Kähönen N, Ingelsson E, 
Johansson A, Kemp J, Kolcic I, Kumar A, Lind L, Melén E, Musk A, Navarro 
P, Nickle D, Padmanabhan S, Raitakari O, Ried J, Ripatti S, Schulz H, Scott 
R, Sin D, Starr J, Viñuela A,  Völzke H, Wild S, Wright A, Zemunik T, Jarvis D, 
Spector T, Evans D, Lehtimäki T, Vitart V, Kähönen M, Gyllensten U, Rudan I, 
Deary I, Karrasch S, Probst-Hensch N, Heinrich J, Koch B, Wilson J, 
Wareham N, James A, Morris A, Jarvelin MR, Sayers I, Strachan D, Hall IP, 
and Tobin M. (2015). Sixteen new lung function signals identified through 
1000 Genomes Project reference panel imputation. Nature Communications.  
Sparvero, L. J., Asafu-Adjei, D., Kang, R., Tang, D., Amin, N., Im, J., . . . Lotze, M. T. 
(2009). RAGE (Receptor for Advanced Glycation Endproducts), RAGE 
ligands, and their role in cancer and inflammation. J Transl Med, 7, 17. doi: 
10.1186/1479-5876-7-17 
Stewart, C. E., Nijmeh, H. S., Brightling, C. E., & Sayers, I. (2012). uPAR regulates 
bronchial epithelial repair in vitro and is elevated in asthmatic epithelium. 
Thorax, 67(6), 477-487. doi: 10.1136/thoraxjnl-2011-200508 
Stewart, C. E., & Sayers, I. (2009). Characterisation of urokinase plasminogen 
activator receptor variants in human airway and peripheral cells. BMC Mol 
Biol, 10, 75. doi: 10.1186/1471-2199-10-75 
Stogsdill, M. P., Stogsdill, J. A., Bodine, B. G., Fredrickson, A. C., Sefcik, T. L., 
Wood, T. T., . . . Reynolds, P. R. (2013). Conditional overexpression of 
receptors for advanced glycation end-products in the adult murine lung 
causes airspace enlargement and induces inflammation. Am J Respir Cell Mol 
Biol, 49(1), 128-134. doi: 10.1165/rcmb.2013-0013OC 
Stoller, J. K., & Aboussouan, L. S. (2005). Alpha1-antitrypsin deficiency. Lancet, 
365(9478), 2225-2236. doi: 10.1016/S0140-6736(05)66781-5 
85 
 
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. 
A., . . . Mesirov, J. P. (2005). Gene set enrichment analysis: a knowledge-
based approach for interpreting genome-wide expression profiles. Proc Natl 
Acad Sci U S A, 102(43), 15545-15550. doi: 10.1073/pnas.0506580102 
Sun, W., & Hu, Y. (2013). eQTL Mapping Using RNA-seq Data. Stat Biosci, 5(1), 
198-219. doi: 10.1007/s12561-012-9068-3 
Syvanen, A. C. (2005). Toward genome-wide SNP genotyping. Nat Genet, 37 Suppl, 
S5-10. doi: 10.1038/ng1558 
Tang, W., Kowgier, M., Loth, D. W., Soler Artigas, M., Joubert, B. R., Hodge, E., . . . 
Cassano, P. A. (2014). Large-scale genome-wide association studies and 
meta-analyses of longitudinal change in adult lung function. PLoS One, 9(7), 
e100776. doi: 10.1371/journal.pone.0100776 
Thurman, R. E., Rynes, E., Humbert, R., Vierstra, J., Maurano, M. T., Haugen, E., . . 
. Stamatoyannopoulos, J. A. (2012). The accessible chromatin landscape of 
the human genome. Nature, 489(7414), 75-82. doi: 10.1038/nature11232 
Uhlen, M., Bjorling, E., Agaton, C., Szigyarto, C. A., Amini, B., Andersen, E., . . . 
Ponten, F. (2005). A human protein atlas for normal and cancer tissues based 
on antibody proteomics. Mol Cell Proteomics, 4(12), 1920-1932. doi: 
10.1074/mcp.M500279-MCP200 
Van Durme, Y. M., Eijgelsheim, M., Joos, G. F., Hofman, A., Uitterlinden, A. G., 
Brusselle, G. G., & Stricker, B. H. (2010). Hedgehog-interacting protein is a 
COPD susceptibility gene: the Rotterdam Study. Eur Respir J, 36(1), 89-95. 
doi: 10.1183/09031936.00129509 
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., . . . 
Zhu, X. (2001). The sequence of the human genome. Science, 291(5507), 
1304-1351. doi: 10.1126/science.1058040 
Visscher, P. M., Brown, M. A., McCarthy, M. I., & Yang, J. (2012). Five years of 
GWAS discovery. Am J Hum Genet, 90(1), 7-24. doi: 
10.1016/j.ajhg.2011.11.029 
Wain L, S. N., Miller S, Jackson V, Ntalla I, Soler Artigas M, Billington CK, Kheirallah 
AK, Allen R, Cook JP, Probert K, Obeidat M, Bossé Y, Hao K, Postma DS, 
Paré PD, Ramasamy A, UK Brain Expression Consortium, Mägi R, Mihailov 
E, Reinmaa E, Melén E, O'Connell J, Frangou E, Delaneau O, OxGSK 
Consortium, Freeman C, Petkova D, McCarthy M, Sayers I, Deloukas P, 
Hubbard R, Pavord I, Hansell A, Thomson NC, Zeggini E, Morris AP, Marchini 
J, Strachan DP, Tobin MD, Hall IP (2015). Novel insights into the genetics of 
smoking behaviour, lung function and chronic obstructive pulmonary disease 
in UK Biobank. The Lancet Respiratory Medicine.  
Wain, L. V., Odenthal-Hesse, L., Abujaber, R., Sayers, I., Beardsmore, C., Gaillard, 
E. A., . . . Hollox, E. J. (2014). Copy number variation of the beta-defensin 
genes in europeans: no supporting evidence for association with lung 
function, chronic obstructive pulmonary disease or asthma. PLoS One, 9(1), 
e84192. doi: 10.1371/journal.pone.0084192 
Wang, K., Li, M., & Hakonarson, H. (2010). Analysing biological pathways in 
genome-wide association studies. Nat Rev Genet, 11(12), 843-854. doi: 
10.1038/nrg2884 
Wang, Z., Gerstein, M., & Snyder, M. (2009). RNA-Seq: a revolutionary tool for 
transcriptomics. Nat Rev Genet, 10(1), 57-63. doi: 10.1038/nrg2484 
Ward, L. D., & Kellis, M. (2012). HaploReg: a resource for exploring chromatin 
states, conservation, and regulatory motif alterations within sets of genetically 
86 
 
linked variants. Nucleic Acids Res, 40(Database issue), D930-934. doi: 
10.1093/nar/gkr917 
Westra, H. J., Peters, M. J., Esko, T., Yaghootkar, H., Schurmann, C., Kettunen, J., . 
. . Franke, L. (2013). Systematic identification of trans eQTLs as putative 
drivers of known disease associations. Nat Genet, 45(10), 1238-1243. doi: 
10.1038/ng.2756 
Wilk, J. B., Chen, T. H., Gottlieb, D. J., Walter, R. E., Nagle, M. W., Brandler, B. J., . . 
. O'Connor, G. T. (2009). A genome-wide association study of pulmonary 
function measures in the Framingham Heart Study. PLoS Genet, 5(3), 
e1000429. doi: 10.1371/journal.pgen.1000429 
Wilk, J. B., DeStefano, A. L., Arnett, D. K., Rich, S. S., Djousse, L., Crapo, R. O., . . . 
Myers, R. H. (2003). A genome-wide scan of pulmonary function measures in 
the National Heart, Lung, and Blood Institute Family Heart Study. Am J Respir 
Crit Care Med, 167(11), 1528-1533. doi: 10.1164/rccm.200207-755OC 
Wilk, J. B., Djousse, L., Arnett, D. K., Rich, S. S., Province, M. A., Hunt, S. C., . . . 
Myers, R. H. (2000). Evidence for major genes influencing pulmonary function 
in the NHLBI family heart study. Genet Epidemiol, 19(1), 81-94. doi: 
10.1002/1098-2272(200007)19:1<81::AID-GEPI6>3.0.CO;2-8 
Wilk, J. B., Shrine, N. R., Loehr, L. R., Zhao, J. H., Manichaikul, A., Lopez, L. M., . . . 
Stricker, B. H. (2012). Genome-wide association studies identify CHRNA5/3 
and HTR4 in the development of airflow obstruction. Am J Respir Crit Care 
Med, 186(7), 622-632. doi: 10.1164/rccm.201202-0366OC 
Wilk, J. B., Walter, R. E., Laramie, J. M., Gottlieb, D. J., & O'Connor, G. T. (2007). 
Framingham Heart Study genome-wide association: results for pulmonary 
function measures. BMC Med Genet, 8 Suppl 1, S8. doi: 10.1186/1471-2350-
8-S1-S8 
Wohlsen, A., Martin, C., Vollmer, E., Branscheid, D., Magnussen, H., Becker, W. M., 
. . . Uhlig, S. (2003). The early allergic response in small airways of human 
precision-cut lung slices. Eur Respir J, 21(6), 1024-1032.  
Wu, L., Ma, L., Nicholson, L. F., & Black, P. N. (2011). Advanced glycation end 
products and its receptor (RAGE) are increased in patients with COPD. 
Respir Med, 105(3), 329-336. doi: 10.1016/j.rmed.2010.11.001 
Xu, S., Grullon, S., Ge, K., & Peng, W. (2014). Spatial clustering for identification of 
ChIP-enriched regions (SICER) to map regions of histone methylation 
patterns in embryonic stem cells. Methods Mol Biol, 1150, 97-111. doi: 
10.1007/978-1-4939-0512-6_5 
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., . . . Schmidt, A. M. (1996). 
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature, 
382(6593), 685-691. doi: 10.1038/382685a0 
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., . . . 
Liu, X. S. (2008). Model-based analysis of ChIP-Seq (MACS). Genome Biol, 
9(9), R137. doi: 10.1186/gb-2008-9-9-r137 
Zhou, J. J., Cho, M. H., Castaldi, P. J., Hersh, C. P., Silverman, E. K., & Laird, N. M. 
(2013). Heritability of chronic obstructive pulmonary disease and related 
phenotypes in smokers. Am J Respir Crit Care Med, 188(8), 941-947. doi: 
10.1164/rccm.201302-0263OC 
Zhou, X., Baron, R. M., Hardin, M., Cho, M. H., Zielinski, J., Hawrylkiewicz, I., . . . 
Silverman, E. K. (2012). Identification of a chronic obstructive pulmonary 
disease genetic determinant that regulates HHIP. Hum Mol Genet, 21(6), 
1325-1335. doi: 10.1093/hmg/ddr569 
87 
 
Zhu, G., Warren, L., Aponte, J., Gulsvik, A., Bakke, P., Anderson, W. H., . . . 
International, C. G. N. I. (2007). The SERPINE2 gene is associated with 
chronic obstructive pulmonary disease in two large populations. Am J Respir 
Crit Care Med, 176(2), 167-173. doi: 10.1164/rccm.200611-1723OC 
 
